DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making

**ABSTRACT**

**Background:** Inflammatory Bowel Disease (IBD) colitis-associated dysplasia is managed with either enhanced surveillance and endoscopic removal or prophylactic colectomy. The rate of progression to cancer after a dysplasia diagnosis remains uncertain in many cases and patients have high thresholds for accepting surgery. Individualised discussion of management options is encouraged to take place between patients and their multi-disciplinary team.

**Aims:** To develop a toolkit to support a structured, multidisciplinary and shared decision-making approach to discussions about dysplasia management options between clinicians and their patients.

**Methods:** Evidence from systematic literature reviews, mixed-methods studies conducted with key stakeholders and decision-making expert recommendations were consolidated to draft consensus statements by the DECIDE steering group. These were then subjected to an international, multidisciplinary modified electronic Delphi process until an a priori threshold of 80% agreement was achieved to establish consensus for each statement.

**Results:** 31 members (15 gastroenterologists, 14 colorectal surgeons and 2 IBD nurses) from 9 countries formed the Delphi panel. We present the 18 consensus statements generated after two iterative rounds of anonymous voting.

**Conclusions:** A toolkit with the consensus recommendations and clinician and patient decision aids have been developed to support shared decision-making when IBD patients are diagnosed with high cancer risk colitis-associated dysplasia.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a well-known risk factor for colorectal cancer development1 but despite the adoption of colonoscopic surveillance, mortality remains higher with colitis-associated cancer compared to sporadic cancers2. Although, most visible dysplasia can now be resected endoscopically there remains a role for cancer-preventative prophylactic colectomy in cases where the dysplasia is endoscopically unresectable or the future risk of cancer is high. Clinician uncertainty in the long-term prognosis of dysplasia3,4 and patients’ understandable reluctance to accept life-changing surgery5–8, especially when they are in clinical remission, make counselling these patients challenging. International society guidelines strongly advocate multidisciplinary discussions about the management of dysplasia to be individualised to the patient, taking into consideration their personal preferences9–12. ﻿Shared clinician-patient decision-making is particularly important when the evidence and best management option is unclear and there are potentially harmful consequences associated with the choice that is eventually made13–15 (i.e. the risk of developing colorectal cancer despite surveillance vs. the risk of having a life-changing surgical complication). On average, IBD patients will only consider having a colectomy if their risk of having a colorectal cancer is 49% or greater5–8. In addition, IBD patients are reassured by having surveillance6,16 despite high post-colonoscopy colorectal cancer rates17. A UK survey study examining how IBD patients wish to be counselled about the management of dysplasia found that a substantial proportion (29%) of the dysplasia-experienced participants did not feel well informed about the associated cancer risk and/or its management by their clinical team8. An international clinician survey has also revealed divergence in colitis-associated dysplasia cancer risk perceptions and management practice, with a reluctance to recommend a proctocolectomy to patients despite a diagnosis of higher-risk endoscopically unresectable low-grade dysplasia (LGD)3.

The objective of the DECIDE steering group has been to develop expert consensus-derived standards for health professionals (gastroenterologists, colorectal surgeons and IBD/pouch/stoma specialist nurses) who counsel patients with colitis-associated dysplasia about their surgical or endoscopic management options. The aim of this consensus guidance is to optimise and standardise the quality of information given to patients and to encourage shared decision-making. It has also informed the content of decision aids for both patients and health professionals to be used to support more confident decision-making.

**METHODOLOGY**

The target population for the statements are adult IBD patients who are diagnosed with colitis-associated dysplasia and are at a higher risk of progression to cancer. These consensus standards were ﻿developed according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology18 and in accordance with the principles of the AGREE II tool19. There were 3 phases to the consensus standards development.

**Phase 1. Systematic literature reviews:** The strategies used to search the Medline, EMBASE, Cochrane and APA PsycInfo databases for articles have been included in the Supplementary material. Article reference lists were additionally hand-searched. Systematic reviews and the highest quality studies or studies reflective of endoscopic/surgical practice in the last two decades were prioritised for inclusion in the evidence narrative summaries.

**Phase 2. Key stakeholder consultation:** Mixed-method survey and interview studies involving key stakeholders were undertaken to explore their lived experiences, dysplasia risk perceptions, management preferences and information communication preferences when counselling or being counselled about the management of colitis-associated dysplasia. ﻿Ethical approval had been granted by the South Central- Berkshire Research ethics committee (REC reference no. 18/SC/0466) and the Health Research Authority and the Health and Care Research Wales bodies. All participants gave informed consent to participate. UK IBD colitis patients (n=123) who are in a surveillance programme or have had a dysplasia diagnosis participated in a survey, which has been previously published8, and/or participated in audio-recorded semi-structured individual interviews (n=25) with thematic analysis of the interview transcripts20,21. A survey of international IBD clinicians (n=294) has also previously been published3. The findings from these studies, together with recommendations by the DECIDE steering group (3 colorectal surgeons, 3 gastroenterologists and an IBD/pouch/stoma specialist nurse) and a health psychologist with expertise in decision-making and risk communication, informed the content of the drafted consensus statements.

**Phase 3. Delphi voting rounds:** A modified electronic Delphi technique22 was used to develop the consensus statements further. Candidates were recruited to the international Delphi expert panel through snowball and purposive sampling. Invitations were advertised via the clinician surveys distributed to members of the British Society of Gastroenterology (BSG) IBD and colorectal sections and the European and Crohn’s and Colitis Organisation3 and via social media. Consensus panel eligibility was based on specific criteria detailed in Supplementary Table 1. The draft consensus statements and evidence narrative syntheses generated from Phases 1 and 2 were presented to the panel electronically. Agreement with the draft consensus statements was voted anonymously through multi-iterative online voting rounds at 4-week intervals. The participants were asked to indicate their level of agreement with each consensus statement using a 5-point Likert scale: strongly agree (A+), agree with minor reservation (A), undecided (U), disagree (D), strongly disagree (D+). They were invited to provide comments, propose additional supportive evidence (own data/grey literature/guidelines) and make suggestions for statement modification. The steering group coordinators modified the statements based on the feedback before re-distribution to the consensus panel for voting. Voting rounds were suspended once there was 80% or more agreement (A+/A) between panel members. GRADE methodology18 has been used to indicate the strength of the recommendation, where a ‘strong recommendation’ reflects that the panel is confident that the desirable effects of an action outweighs the undesirable effects and a ‘weak recommendation’ reflects when there is uncertainty in the balance. The level of agreement with each statement is described as the percentage of the panel that voted in agreement (A+/A). The quality of evidence for each final agreed statement has been ranked also using GRADE methodology18 as agreed by the consensus panel members (Supplementary Table 2).

**RESULTS**

Thirty-one members from nine countries formed the Delphi international expert consensus panel. Two iterative anonymous voting rounds were conducted before >80% consensus agreement (A+/A) for each of the 18 statements was achieved. In the final voting round, 30 of the 31 Delphi panel members responded. The final consensus statements are listed in Table 1. Details of the members of the DECIDE steering group and the Delphi consensus panel have been included in Supplementary Table 4 and summarised in Table 2.

**Table 1. DECIDE consensus panel recommendations on the management and counselling of patients with colitis-associated dysplasia.**

\*A+/A % = % Level of agreement; SOR = Strength of recommendation; QoE = Quality of Evidence

|  |  |  |  |
| --- | --- | --- | --- |
| **STATEMENTS** | **A+/A**  **%** | **GRADE** | |
| **SoR** | **QoE** |
| 1. We recommend that all patients diagnosed with colitis-associated dysplasia are discussed in a multidisciplinary team meeting to achieve consensus on the future recommended management and ensure documentation. To achieve a quorate meeting, attendance of at least one gastroenterologist and one colorectal surgeon is required, including an endoscopist with expertise in advanced therapeutic or IBD surveillance colonoscopy and optical characterisation of advanced colonic lesions. | 100% | Strong | Low |
| 1. We recommend that unifocal colitis-associated dysplasia that has been successfully endoscopically resected can be managed with continued surveillance, performed by an experienced IBD endoscopist using high definition white light and image enhanced endoscopy. However, these patients should still be counselled about their long-term risk of metachronous advanced neoplasia and how this risk can be mitigated. | 96.7% | Polypoid LGD: | |
| Strong | Low |
| Non-polypoid dysplasia/HGD: | |
| Weak | Very low |
| 1. We suggest that a patient with colitis-associated visible dysplasia is referred to a regional endoscopy centre with expertise in advanced polypectomy if:    1. there is uncertainty about the endoscopic resectability of the lesion despite local expertise,    2. there are no macroscopic features suggestive of submucosal invasion    3. the patient consents. | 96.7% | Weak | Very low |
| 1. We recommend that patients with colitis-associated dysplasia, who are at a higher risk of cancer development and are appropriate surgical candidates, should be counselled carefully about the benefit of prophylactic colectomy over continued surveillance. High cancer risk factors include presence of at least one of the following:    1. Lesion-specific characteristics e.g. high-grade dysplasia, large non-polypoid morphology, multifocal, invisible or endoscopically unresectable dysplasia, and    2. Patient-specific risk factors e.g. previous dysplasia, primary sclerosing cholangitis, active colonic inflammation, colonic stricture, or family history of colorectal cancer. | 100% | Strong | Low |
| 1. We suggest that patients with higher-risk colitis-associated dysplasia who need to be counselled about surgery have a joint consultation with a gastroenterologist and colorectal surgeon. Clinics may ideally be coordinated to run as a combined multidisciplinary clinic or in parallel clinics to facilitate this and include a specialist nurse with expertise in IBD and/or stoma and pouch care. | 100% | Weak | Very low |
| 1. We recommend that the principles of shared decision-making are used when counselling patients about the risks and benefits of endoscopic or surgical management of colitis-associated dysplasia. Numerical and individualised risk estimates should be communicated where possible. If there is uncertainty due to low-quality data and an individualised risk cannot be given, then information about their risk factors comparative to an IBD patient without risk factors can facilitate risk comprehension. | 100% | Strong | Very low |
| 1. We suggest that these patients are made aware of their alternative management options, the associated risks and benefits and whether these are suitable in their case.    1. Enhanced endoscopic surveillance and management, or    2. Surgical management:       * 1. Panproctocolectomy and permanent ileostomy         2. Restorative proctocolectomy with ileoanal pouch formation         3. Less extensive and rectum-preserving surgery in selected cases (e.g. ileorectal anastomosis or segmental colectomy), or    3. No surgery or endoscopic management. | 96.7% | Weak | Very low |
| 1. We recommend that patients are informed of the risks and benefits of continued colonoscopic surveillance after a dysplasia diagnosis.   The benefits may be that:   1. Surgery is avoided in the short-term, particularly for those with a high risk of peri-operative complications, and 2. Current bowel function may not change if their colitis remains quiescent.   The risks may include the:   1. Need for more frequent colonoscopies and polypectomies with their associated risks of bleeding and perforation 2. Continued long-term risk of developing active colitis requiring medical therapy or surgery 3. Continued long-term risk of developing a cancer due to the limitations of surveillance. When detected these cancers may be at an advanced stage, associated with a poorer prognosis and therefore may require more extensive surgery, chemotherapy and/or radiotherapy. | 100% | Risk of cancer despite surveillance: | |
| Strong | Moderate |
| Patient-reported outcomes: | |
| Strong | Very low |
| 1. We recommend that patients being counselled about surgery are informed of their operative morbidity and mortality risks, based on their comorbidities, functional status and institutional data. Shorter-term general complications may include wound healing delays, anastomotic leak, infections, venous thrombosis, bleeding and small bowel obstruction or ileus. Most can be treated medically but some will require re-operation. Mortality is low (< 1% risk). A role for laparoscopic or less extensive colectomy surgery, which carry the lowest complication risks, may be discussed if the expertise is available and the patient is an appropriate candidate. | 90% | Mortality: | |
| Strong | Moderate |
| General complications: | |
| Strong | Low |
| 1. We recommend that patients being counselled about a proctocolectomy, should be informed of further potential complications associated with the pelvic dissection required for a proctectomy:    1. Sexual dysfunction. Erectile or ejaculatory dysfunction can occur in 3% or less of men post-operatively but this is least likely in men younger than 50 years and is often treatable with medical therapy. More women may experience dyspareunia post-operatively. However, overall long-term sexual function and satisfaction does not deteriorate in the majority of both men and women post-operatively.    2. Reduced fecundity, i.e. a reduced ability to conceive during a period of unprotected sexual intercourse. However, this risk may be lower after laparoscopic surgery compared to open surgery.   The negative implications of uncontrolled inflammatory disease on sexual function and fecundity should also be discussed. | 100% | Sexual function: | |
| Strong | Low |
| Fecundity: | |
| Strong | Very low |
| 1. We recommend that patients being counselled about a panproctocolectomy and permanent ileostomy, should be informed of the potential advantages and disadvantages over other surgical options.   The advantages to be considered are that:   1. Complete removal of colonic and rectal tissue will eliminate any further risk of colorectal cancer or colitis-associated symptoms (although Crohn’s patients may get recurrence at other sites) 2. Surgery can be performed in one operative stage electively 3. Stomas can allow better bowel control than a pouch in some cases. Overall quality of life has been shown to be high post-operatively and similar to pouch surgery patients.   The disadvantages to be considered are:   1. Stoma-related complications (20-30% risk of a re-do operation over 10 years; risk highest in Crohn’s patients) 2. The possible impact of a permanent stoma on body image, diet and work/social function 3. The potential negative impact of a proctectomy on sexual function and fecundity. | 100% | Patient-reported outcomes and stoma-related complications: | |
| Strong | Low |
| 1. We recommend that patients being counselled about a restorative proctocolectomy with ileoanal pouch anastomosis, are informed of the following potential advantages and disadvantages over other surgical options.   The advantages to be considered are that:   1. Removal of all colonic and most of the rectal tissue will significantly diminish future risk of colorectal cancer, and 2. They may have improved colitis-associated symptoms if they have active and uncontrolled disease pre-operatively 3. It allows the maintenance of bowel evacuation via the anus and avoidance of a permanent stoma in most cases.   The potential disadvantages to be considered are:   1. This operation may not be suitable for selected individuals due to higher complication rates. Pouch surgery is not recommended for patients with impaired anal sphincters, perianal disease, or low rectal neoplasia. Patients with Crohn’s colitis or primary sclerosing cholangitis should be informed of the elevated complication rates associated with pouch surgery in these groups 2. The need for 2 or 3 stages of operations and therefore a longer recovery time 3. The operation may not be offered at their local hospital and therefore may require longer distance travel 4. They may experience symptoms from their pouch that are more troublesome than what they are currently experiencing (normal pouch function is 3-8 times a day with the additional risk of problems e.g. pouchitis). This may have an impact on their diet and work/social function 5. The potential negative impact of pouch surgery on sexual function and fecundity 6. Although the absolute risk of pouch cancer is low (< 1% at 10 years post-operatively), prior neoplasia is associated with up to a 9-fold relative increased risk. Therefore, these patients would be recommended to have a yearly surveillance pouchoscopy. | 93.3% | Pouch function and complications: | |
| Strong | Low |
| Health-related quality of life: | |
| Strong | Low |
| Post-operative cancer risk: | |
| Strong | Moderate |
| 1. We suggest that in some selected cases of colitis-associated dysplasia less extensive surgery, such as total or subtotal colectomy with ileorectal anastomosis or segmental colectomy with primary anastomosis, may be considered. These selected cases may include patients with a higher operative risk (due to older age or multiple comorbidities) or are younger and have concerns about maintaining fecundity and sexual function or they have segmental Crohn’s colitis. They would need to have rectal sparing of inflammation and dysplasia, and normal anal sphincter function and rectal compliance.   The potential advantages are that these less extensive surgeries are:   1. Likely to be associated with a reduced cancer risk compared to continued surveillance due to removal of the affected part of the colon 2. They allow the maintenance of bowel evacuation via the anus and avoidance of a stoma 3. They can be completed in one operative stage 4. They do not require extensive pelvic dissection, minimising the risk of sexual dysfunction or reduced fecundity   The potential disadvantages are:   1. Active inflammation recurrence in the colonic or rectal remnant left in situ may occur, requiring an escalation in medical therapy and potentially further bowel resection if medically refractory 2. Patients may experience more urgency after an ileorectal anastomosis, but frequency and continence is normally better than experienced with ileoanal pouches 3. A greater cancer risk will exist compared to those who choose proctocolectomy surgery and which will require ongoing annual endoscopic surveillance with its attendant limitations (highest risk after segmental colectomy; reported as high as 25% cancer risk over 10 years if subtotal colectomy with ileorectal anastomosis for pre-operative dysplasia). Cancers being diagnosed at an advanced stage would be associated with a poorer prognosis and may require more extensive surgery and oncological therapy. | 90% | Patient-reported outcomes: | |
| Weak | Low |
| Post-operative colitis recurrence: | |
| Strong | Low |
| Post-operative cancer risk: | |
| Weak | Low |
| 1. We recommend that patients with colitis-associated dysplasia who decline surgical or endoscopic management should be informed of their risk of developing colorectal cancer. In the short-term they may avoid disruption to their quality of life from these interventions. However, if they develop cancer in the future their quality of life will likely be reduced by more advanced disease requiring significantly more aggressive oncological interventions. | 100% | Strong | Very low |
| 1. We recommend that patients with colitis-associated dysplasia who are considering surgery, should meet with a specialist nurse to discuss stoma and pouch care and the likely impact of these on quality of life. | 100% | Strong | Very low |
| 1. We suggest that patients with colitis-associated dysplasia who are considering surgery are signposted to patient support groups or charities and be given the opportunity to speak to other patient advocates about life with a stoma or pouch in order to support their decision-making. | 93.3% | Weak | Very low |
| 1. We recommend that patients with colitis-associated dysplasia, who are deciding between continued endoscopic management or colectomy, be given time to consolidate information, deliberate and ask any further questions of their clinical team after the initial consultation. Use of a visual decision aid (leaflet, video or online material) to facilitate this is encouraged. | 96.7% | Strong | Moderate |
| 1. We recommend that these patients be offered a second consultation, with ideally the same clinicians, if they have not made a decision after the first joint consultation. Any gaps in understanding and further queries should be addressed and the consultation should conclude with an informed preference-based decision by the patient. | 100% | Strong | Very low |

**Table 2. Summary of Delphi panel member demographics**

|  |  |
| --- | --- |
| **Delphi panel member demographics** | **N = 31** |
| Clinical role   * Colorectal Surgeon * Gastroenterologist * IBD/pouch/stoma nurse specialist | 14  15  2 |
| Country of origin   * Australia * Belgium * Canada * Greece * Italy * Netherlands * Sweden * Turkey * United Kingdom | 2  1  1  2  2  1  1  1  20 |
| Workplace affiliation   * Tertiary / academic hospital * Secondary / general hospital | 26  5 |

**DISCUSSION**

**DYSPLASIA PATIENT RISK STRATIFICATION AND MANAGEMENT**

International consensus dictates that surveillance colonoscopy can be continued after endoscopically visible dysplasia has been fully resected and there is no other unresectable dysplastic change in the colonic mucosa9–11,23. The pooled estimated cancer incidence after endoscopic resection of polypoid dysplasia in ulcerative colitis (UC) patients on surveillance follow-up (n=376) in a meta-analysis was low at 0.5 cases per 100 patient-years24. A multi-centre cohort study of UC patients (n=460) who had surveillance follow up for a median 4.1 years after a LGD diagnosis calculated incidences of advanced neoplasia [high-grade dysplasia (HGD) and cancer] after endoscopic resection of unifocal polypoid and non-polypoid dysplasia to be 0.7 (95% CI 0.3 - 1.3) and 2.5 (95% CI 1.2 – 4.7) cases per 100 patient-years respectively25. The lowest rates of progression to advanced neoplasia are reported by studies where high-definition imaging and/or chromoendoscopy surveillance have been used and *en bloc* endoscopic resection has been histologically confirmed with clear R0 resection margins4,26.

Larger and non-polypoid colitis-associated dysplastic lesions are particularly more difficult to resect fully due to the underlying inflammation-induced submucosal fibrosis27. Endoscopists and endoscopy centres with higher volume experience in polypectomy have greater reported R0 resection rates and lower post-colonoscopy colorectal cancer rates17,28,29. Therefore, it is recommended that these lesions are resected by endoscopists with advanced polypectomy expertise in endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) or hybrid techniques. Not all endoscopists who perform IBD surveillance have this specialist expertise30. Therefore, if the expertise is not available locally, referral to a regional therapeutic endoscopist or endoscopy centre is suggested. Although most reported advanced neoplasia rates after endoscopic resection of non-polypoid dysplasia from specialist therapeutic endoscopy centres have been low4, case series where ESD of large (>2cm) lesions have resulted in variable R0 resection success rates have still demonstrated progression rates to cancer of 22-40% with LGD and 50% with HGD31,32.

Careful optical characterisation of lesions at endoscopy is required to determine the likelihood of successful *en bloc* resection. Visible dysplasia that is endoscopically unresectable is a significant risk factor for cancer and should be managed with surgical resection rather than continued surveillance9–12. Lesions are unlikely to be successfully endoscopically resected if the borders of the lesion are non-delineated or there are features of submucosal invasion or significant submucosal fibrosis such as irregular surface architecture, mucosal depression, converging mucosal folds or failure to lift with submucosal injection33. In any case of doubt careful photo or video documentation and discussion together with careful placement of a tattoo should be followed by discussion at a multidisciplinary team (MDT) meeting either locally or at a regional centre. Expert consensus-derived standards of care have advocated MDT meetings as an important aspect of general IBD patient care34–37. To achieve a quorate meeting, attendance of at least one gastroenterologist and one colorectal surgeon is required, including an endoscopist with expertise in advanced therapeutic or IBD surveillance colonoscopy and optical characterisation of advanced colonic lesions. Inclusion of the latter would allow prompt decisions to be made on the suitability of a dysplastic lesion for endoscopic or surgical management locally or regionally. The panel also recognises the importance of a gastrointestinal histopathologist’s role within the MDT and the requirement for two expert histopathologist confirmation of a dysplasia diagnosis, as per international guideline recommendations9–11. The consensus panel encourages that all patients diagnosed with colitis-associated dysplasia, even if resected at endoscopy, are discussed at an MDT meeting to facilitate a more holistic consideration of the patient’s future cancer risk when decision-making. The MDT discussion should recognise the implications of other co-existent cancer risk factors (e.g. primary sclerosing cholangitis), or where effective continued surveillance is difficult (e.g. active inflammation, extensive post-inflammatory mucosal change or strictures), and confirm future surveillance intervals or need for surgical consideration. Clinician survey studies have shown variation in dysplasia management practice, demonstrating that gastroenterologists may be less likely to advocate colectomy for high-risk dysplasia than colorectal surgeons38 or if they work in a non-tertiary care centre, which may be a result of decreased access to specialist MDT meetings3. A theme derived from the interviews conducted with the DECIDE patient stakeholders, was that patients were more likely to trust their clinician’s management recommendations, despite the uncertainty in their cancer risk, if they knew that there was MDT-based peer consensus (Supplementary Appendices 2).

Patients should be made aware of their continued long-term risks of metachronous advanced neoplasia despite endoscopic resection of dysplasia and surveillance follow-up. Colitis-associated cancers appear to display molecularly distinct differences which confer a more aggressive phenotype to sporadic cancers39–42. Occult clonal evolution of neoplasia-promoting genetic changes in colitis is detectable throughout the entire colon long before the development of clinically detectable neoplasia, indicative of a ‘field cancerisation’ effect, which may explain the increased incidence of multifocal synchronous and metachronous cancers in IBD39,40. Patients should be counselled about how they can mitigate their own cancer risk. This includes complying with medications to optimise disease control and adhering to scheduled surveillance intervals and bowel preparation instructions for effective surveillance. Patients should be counselled about any additional risk factors they may have which places them in a higher cancer risk category and where the benefit of prophylactic colectomy may now supersede long-term endoscopic management. This is especially the case if a patient has more than one risk factor as the risk of advanced neoplasia appears to increase cumulatively with each additional risk factor25,43. A list of known clinical patient and lesion-specific risk factors for cancer progression after a dysplasia diagnosis is presented in Table 3.

**Table 3. Clinical patient and lesion-specific risk factors for advanced neoplasia progression after a dysplasia diagnosis**

\*HGD = high-grade dysplasia; LGD = low-grade dysplasia; OR = Odds ratio; HR = Hazards ratio; RR = Relative risk; CI = confidence interval

|  |  |
| --- | --- |
| **Risk factors** | **Risk of progression to advanced neoplasia\*** |
| **Primary Sclerosing Cholangitis** | LGD progression to advanced neoplasia:   * Meta-analysis44, **OR 3.4** (95% CI 1.5–7.8; 3 studies) * Univariate analysis, Dutch and USA multicentre cohort45, **HR 2.5** (95% CI 1.2-5.3; n=355) |
| **Previous dysplasia** | LGD progression to advanced neoplasia:   * Belgian multicentre cohort46, **RR 6.99** (95% CI 1.5-31.8; n=410)   Indefinite for dysplasia progression to advanced neoplasia:   * Multivariate analysis of UK cohort43, **HR 2.8** (95% CI 1.2-6.5; n=172) |
| **Increased colonic inflammatory burden** | UK multicentre cohort study25, cumulative inflammatory burden or recent (last 5 years) of moderate-severe active histological inflammation independently predicts LGD progression to advanced neoplasia, **HR 3.1** (95% CI 1.5-6.7; n=248) |
| **Presence of a colonic stricture** | LGD progression to advanced neoplasia:   * Multivariate analysis of Belgian multicentre cohort46, **RR 2.64** (95% CI 1.00-6.96; n=410) * Univariate analysis in UK cohort43, **HR 7.4** (95% CI 2.5-22.1; n=172). |
| **Patient demographics** | LGD progression to advanced neoplasia, multivariate analysis Dutch population-based cohort47:   * Age 55 years or more, **HR 1.7** (95% CI 1.4-2.1; n=4284) * Male sex, **HR 1.3** (95% CI 1.1-1.6; n=4284) |
| **Family history of colorectal cancer** | Foundto be an independent risk factor associated with a 2 to 4-fold increase in cancer incidence in IBD population-based and multicentre cohort studies48,49, although not a significant independent factor for advanced neoplasia progression in established dysplasia46. |
| **Multifocal dysplasia** | LGD progression to advanced neoplasia:   * Meta-analysis44, **OR 3.5** (95% CI 1.5–8.5; 3 studies) * Multivariate analysis of UK cohort25, **HR 2.9** (95% CI 1.3-6.2; n=248) |
| **Endoscopically unresectable or incompletely resected dysplasia** | LGD progression to advanced neoplasia:   * Multivariate analysis of UK multicentre cohort25, **HR 3.4** (95% CI 1.6 – 7.4; n=246) * HGD/cancer incidence25 = **5.2 per 100 patient-years** (95% CI 1.9-11.5) if unifocal LGD * HGD/cancer incidence25 = **19.3 per 100 patient-years** (95% CI 10.5-32.8) if multifocal LGD |
| **Visible HGD** | Synchronous cancer rate in colectomy specimen soon after pre-operative visible HGD:   * Historically associated withhigh rates of synchronous cancer (as high as 45%)50–53. * More recent studies from the videoendoscopic high-definition imaging era have suggested lower but still significant rates4,54,55. Pooled synchronous cancer rate = 13.7% (95% CI 0.0 – 54.1; I2>50%; n=126; 3 studies; GRADE quality of evidence considered very low)4   Colorectal cancer progression rate despite surveillance after endoscopic resection of HGD:   * Systematic review4: 0 – 40% after a median of 4 years if polypoid morphology and up to 50% after a median of 11 years if non-polypoid morphology. * Belgian retrospective multicentre cohort46 (where half of the lesions were nonpolypoid, and 85% were endoscopically resected):14.8% (n=4/27) developed a cancer over median follow-up of 6.4 years (IQR 3.8- 9.9). |
| **Invisible HGD** | Synchronous cancer rate in colectomy specimen soon after pre-operative visible HGD4:   * Pooled synchronous cancer rate = 11.4% (95% CI 4.6-20.3%; n=69; 2 studies; GRADE quality of evidence considered very low).   Colorectal cancer progression rate despite surveillance after invisible HGD diagnosis:   * Cleveland clinic cohort56: 27.3% (n=6/22) progressed to cancer after only a median follow up time of 6.8 months |
| **Large diameter, non-polypoid dysplasia** | LGD progression to advanced neoplasia:   * UK multicentre cohort multivariate analysis25, lesion diameter of 1cm or more, **HR ﻿2.7** (95% CI 1.2 to 5.9; n=246) regardless of whether lesions fully endoscopically resected or not * UK single centre cohort multivariate analysis (n=172)43, non-polypoid morphology **HR 8.6** (95% CI 3.0–24.8) compared to polypoid morphology, but not adjusted for resection status * Belgian multicentre cohort (n=410)46, non-polypoid morphology **RR 13.8** (95% CI 3.1-61.2) compared to polypoid morphology, but not adjusted for resection status   Most case series reporting on ESD or hybrid techniques performed in specialist centres for large non-polypoid dysplastic lesions imply good prognoses if clear resection margins are achieved and these patients are followed up closely with high quality surveillance4. However, small populations, and limited follow-up times and some with low R0 resection rates report high progression rates to cancer (22-40% with LGD and 50% with HGD)31,32 |
| **Invisible LGD** | * Meta-analysis4, pooled estimated synchronous cancer rate = 2.4% (95% CI: 0.0-8.5%; I2>50%; n=208; 3 studies; GRADE quality of evidence considered very low) compared to a more historical pooled analysis (22%; n=18/81; 10 studies)57. * Multivariate analyses: invisible morphology is an independent predictor of LGD progression to advanced neoplasia, with a 2-3-fold increased risk in the longer-term25,44. * Data from the most recent studies where high-definition imaging and/or chromoendoscopy routinely used for surveillance follow-up have shown conflicting results25,58:   + Dutch multicentre cohort surveillance study58, 3.8% (n=1/26) with invisible LGD developed cancer over a median of 5 years follow-up   + UK multicentre UC cohort study25, cancer incidence for unifocal invisible LGD = 4.3 per 100 patient years (95% CI 1.9 – 8.6; n=7/42) |

Invisible and endoscopically unresectable HGD is associated with a high risk of cancer and therefore recommendation for colectomy in this cohort is justified55,56. There remains some equipoise in international guidelines as to the best management of invisible LGD due to the lower quality of evidence available and the acceptance that many of the ‘invisible’ lesions detected in historical studies likely would have been visible using modern day high-definition and chromoendoscopic imaging by an experienced endoscopist58,59. Therefore, the incidence of synchronous cancers detected in colectomy specimens resected for a pre-operative diagnosis of invisible LGD are much lower in the more modern era (Table 3). Some may find it acceptable for a patient with unifocal invisible LGD to undergo a period of intensive and high-quality surveillance, rather than proceed immediately to colectomy33. However, patients should be made aware that the long-term data on invisible dysplasia are of low quality, mainly due to the inclusion of small numbers4,44. Multivariate analyses (Table 3) have shown that invisible morphology is an independent predictor of LGD progression to advanced neoplasia, with a 2 to 3-fold increased long-term risk and therefore colectomy should be discussed with these patients25,44.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**INITIAL CONSULTATION WITH PATIENTS WITH HIGH CANCER RISK COLITIS-ASSOCIATED DYSPLASIA**

Patients with colitis-associated dysplasia and one of the risk factors detailed in Table 3 are at a high-risk of developing cancer in the longer term. If they are an appropriate surgical candidate based on their age and comorbidities, it would be prudent to counsel these patients of the benefits of prophylactic colectomy surgery as an alternative management to continued colonoscopic surveillance. There was panel consensus that this consultation would ideally take place in a clinic setting with the core members of the MDT all jointly present, namely a gastroenterologist, colorectal surgeon and an IBD and/or a stoma and pouch care specialist nurse. Access to both surgical and gastroenterologist expertise at the same time for patients considering surgical or medical management is advocated by UK IBD standards of care12,36 and preferred by patients60,61, including the DECIDE patient stakeholders who felt that it would increase decision-making confidence (Supplementary Appendices 2). Initial discussions about surgery are often with the patient’s gastroenterologist and framed as ‘a last resort’62–65. Therefore, earlier introduction of surgery as an alternative treatment option, framed in more positive terms, has been advocated to enable more informed decision-making64,66. Although consultations would ideally occur in either a dedicated combined/joint medical-surgical clinic or clinics that run in parallel at the same time and location, the consensus panel recognise the logistical challenges of delivering this aspirational recommendation in all centres.

In the case of colonic dysplasia, a trade-off in risks needs to be considered when deciding between having life altering colectomy surgery or continuing surveillance with the ongoing risk of developing a metachronous cancer. Patient-centred relationships with trusted clinicians engaged in shared decision-making are associated positively with increased patient comprehension of the risks and benefits of treatments and increased satisfaction with the patient’s role in decision-making62,67. IBD patients value preference-based shared decision-making highly68, but it does not appear to be routinely practised69. To facilitate shared decision-making a multi-step process should occur (Figure 1)14,15,70–72. The risks and attributes that IBD patients most highly value when making decisions about their treatment include (i) the impact on symptoms including pain, bowel urgency and fatigue, (ii) the risks of cancer and serious infections within the next 10 years, anaesthetic-related complications, and other mild-moderate complications, (iii) and the impact on longer-term health-related QOL including their emotional status, diet, ability to complete daily tasks, their sexual and social life and interpersonal interactions73,74.

Procedural and cancer risks should be communicated effectively to maximise patient comprehension (Supplementary Table 5). The majority of the DECIDE patient stakeholders indicated that personalised cancer risk communication would make them feel better informed and more confident in their decision-making (Supplementary Appendices 2). In order to support more individualised cancer risk communication, a risk prediction tool which displays cancer risk in a Paling chart format for UC patients with LGD has been developed and externally validated ([www.uc-care.uk](http://www.uc-care.uk))25.

Valid informed consent requires that all alternative treatment options are discussed including riskier options such as doing nothing75,76. IBD patients have expressed a desire to be given more information about alternative treatment options earlier in their disease course to make more informed decisions62,69. Endoscopic treatment options for dysplasia include polypectomy and/or more intensive surveillance monitoring. Proctocolectomy (with either a permanent ileostomy or an ileoanal pouch anastomosis) is advocated as the surgical option of choice for higher cancer risk colitis patients, but the alternative surgical options of less extensive rectum-preserving colectomy (subtotal colectomy with ileorectal anastomosis or segmental colectomy) may be discussed with selected patients12,77,78. Discussions regarding the preferred choice of management will also be influenced by local expertise and availability. Not all centres have access to ESD or pouch surgery and some centres may be able to provide continent ileostomy as an alternative surgical option. A decision grid summarising the advantages and disadvantages of each management option has been constructed to aid more comprehensive communication with patients during the consultation (Supplementary Appendices 3).

**Figure 1. Multi-step process to use when making shared decisions with a patient**

|  |
| --- |
| 1. Explain that a choice needs to be made between several management options, each with its own risks and benefits 2. Make it clear that the patient has a central role in the discussion and that their preferences are essential to make a decision 3. Relay information regarding all the management options to the patient, acknowledging where there is uncertainty 4. Elicit the patient’s values and goals with particular emphasis on what is important to them to maintain their long-term quality of life, e.g. bowel function, diet, work, interpersonal relationships, family life, fecundity 5. Consider these values and what the patient is willing to trade-off when comparing the risks and benefits of each management option 6. Encourage patient engagement by limiting medical terminology, allowing time for deliberation and further questions, before agreeing on a decision based on the patient’s informed preferences. |

1. **Endoscopic management of higher-risk colitis-associated dysplasia**

Colitis patients often prefer to continue surveillance and endoscopic management after a high-risk dysplasia diagnosis, especially those in clinical remission5–8. The DECIDE patient stakeholders wanted to avoid or delay colectomy surgery due to concerns about its impact on their quality of life and mental wellbeing and due to other familial and societal pressures (Supplementary Appendices 2). Although the prospect of frequent colonoscopies is not attractive to patients due to the associated discomfort from the procedure and bowel preparation and feelings of embarrassment and vulnerability, they are reassured by the protection that colon surveillance offers79. Studies of patient-reported outcomes suggest that IBD surveillance patients overall have a good quality of life and comparable anxiety and coping ability scores to lower cancer risk patients not yet on a surveillance programme8,80,81. Although patients continuing surveillance may be able to avoid surgery in the short-term and may maintain their bowel function if their colitis remains quiescent, they should be counselled of the risk of developing active inflammation, which may need medical therapies and/or surgery in the long-term, and the associated greater future cancer risk.

IBD patients tend to overestimate the benefit that colonoscopic surveillance carries in reducing their cancer risk and these expectations should be managed appropriately5,6. Post-colonoscopy colorectal cancer rates are significantly elevated at 35.5% in IBD patients and do not appear to be falling despite improvements in surveillance quality17. These are considered to occur where (i) dysplastic lesions may have been missed often due to inadequate bowel preparation, active inflammation or post-inflammatory mucosal changes or (ii) where the colon appears to be primed for a biologically more aggressive neoplastic evolution process indicated by the presence of active inflammation or previous dysplasia or (iii) the recommended surveillance interval or surgical management has not been adhered to82–86. Patients who poorly tolerate bowel preparation or the procedure itself may find it difficult to comply with annual or more frequent colonoscopy. The quality of surveillance undertaken, as dictated by factors such as the procedural frequency, quality of the mucosal visualisation, equipment availability, and the expertise of the endoscopist all need to be borne in mind when counselling patients about their long-term cancer risk and potential for missed neoplastic lesions despite surveillance. Continued surveillance after a dysplasia diagnosis should be performed by an endoscopist deemed to have appropriate experience in IBD surveillance and with access to high-definition imaging and virtual or dye chromoendoscopy33. Patients should be counselled about the consequences of developing a colitis-associated colorectal cancer despite surveillance, which is associated with a poorer prognosis compared to sporadic cancers and the possibility of it being incurable at diagnosis2,87. Compared to a proctocolectomy performed for LGD, a cancer diagnosis may require more extensive surgical pelvic dissection and chemotherapy and/or radiotherapy with a greater consequence on quality of life, sexual function and fecundity.

The risks of a diagnostic surveillance colonoscopy are low, but the risks of peri-procedural complications with advanced polypectomy techniques, particularly if there are large, multiple or recurrent lesions, should be explained where indicated26,27,88. In a meta-analysis89 of 11 studies with 506 IBD patients (610 dysplastic lesions; mean diameter 23mm) who underwent EMR, ESD or hybrid ESD, pooled perforation rates were 0%, 3.8% and 4.1% respectively and pooled bleeding rates were 1.4%, 2.3% and 9.5% respectively. Reassuringly, however, most of these complications can be managed endoscopically without the need for surgical intervention. Patients may need to travel to a regional centre if they have a complex dysplastic lesion requiring EMR or ESD. The patient’s preferences should be obtained prior to the referral as they may not wish to travel if the centre is far from home and there is a risk of needing admission post-procedure. Despite the practical difficulties, the IBD patient stakeholders informing these consensus statements welcomed a referral for a second opinion in a regional centre if it could mean safely avoiding colectomy (Supplementary Appendices 2).

1. **Surgical management of higher-risk colitis-associated dysplasia**

The recommended surgical option for colitis-associated dysplasia is proctocolectomy12,77,78,90–92. Panproctocolectomy with excision of all anorectal tissue and perineal closure and formation of a permanent ileostomy may be preferred over restorative proctocolectomy with ileoanal pouch anastomosis (IPAA) as it eradicates UC and long-term colorectal cancer risk12. Given the segmental nature of Crohn’s colitis and the risk of recurrence throughout the gastrointestinal tract, less extensive (including segmental) colectomy, may be considered in selected cases78,91,92. A less extensive colectomy with anastomosis is associated with lower complication rates compared to proctocolectomy93–96. Due to its lower associated morbidity, subtotal colectomy with IRA may also be considered in carefully selected cases of older, more comorbid UC patients with a higher peri-operative risk12,77,90. Unlike with proctocolectomy, rectum-preserving colectomy surgery is not associated with sexual dysfunction97,98 or reduced fecundity99, therefore selected younger UC patients may want to consider a subtotal colectomy and IRA12,77,90. Patients being considered for an IRA should meet the following criteria: the neoplasia is located in a proximal colonic segment, their rectal disease is quiescent or mild, there is reasonable rectal and anal sphincter function, there is a low risk of dysplasia in the retained rectum and they are willing to comply with postoperative surveillance of the rectal remnant12,77,90. Although less extensive colectomy is inferior to proctocolectomy in terms of long-term metachronous neoplasia risk, several of the stoma and pouch averse DECIDE patient stakeholders expressed being more accepting of surgery if less extensive colonic resection and a primary anastomosis was proposed (Supplementary Appendices 2). They preferred more detailed information on this management option, even if it was not suitable for them, to feel better informed. If they had felt that they had not been given sufficient information by a surgeon, they sought further information via patient support groups or their IBD nurses. It is essential that patients considering less extensive colectomy are willing to adhere with regular endoscopic surveillance of the remaining colorectum and are well informed about the risks of needing further medical or surgical therapy if they were to develop active inflammatory disease or cancer. Complications associated with chemoradiotherapy or extensive surgical pelvic dissection planes needed for satisfactory oncological treatment should be mentioned as well as the possibility of a late cancer diagnosis being incurable.

Restorative proctocolectomy with IPAA is normally performed in 2 to 3 staged operations and is only offered by specific institutions. The longer recovery time and travel distance from home to the hospital for multi-stage operations, re-admissions for complications and outpatient follow-up may have personal financial as well as functional implications that need to be considered when decision-making. The UK Surgical Workload Outcomes Audit Database (SWORD)100 identified a national average 30-day re-admission rate after pouch surgery of 27.4% (range between regions 21-31%) and a national average 30-day re-operation rate of 6% (range between regions 3-11%). Panproctocolectomy and end ileostomy formation is normally performed in one operation, which may make it a more attractive option for patients who desire less elective hospital admissions and a shorter overall recovery time. A continent ileostomy (e.g. Kock pouch) may be considered in some selected cases. A systematic review of continent ileostomy outcomes indicates good quality of life outcomes but reoperation rates due to complications are high (20.8 – 65%)101.

The risks associated with proctocolectomy or less extensive colectomy are influenced by a number of factors which are specific to the patient (age, comorbidities and functional performance status), operating surgeon and institution. Surgeons are expected to have detailed discussions regarding these risks when consenting patients for surgery. This level of detail is outside of the remit of these consensus standards, however, the DECIDE steering group agreed that in order to have transparent discussions when counselling IBD dysplasia patients about management, it would be helpful for non-surgeons (gastroenterologists, trainees and specialist nurses) to have some evidence-based and consensus-agreed general surgical risk information as presented here.

* 1. **General complications:**

**Mortality** is low (< 1% risk) after colectomy surgery but increases with factors such as increased patient comorbidities102–105. **General shorter-term morbidity** related to colectomy surgery may include wound healing delays, anastomotic leak, infections, venous thrombosis, bleeding and small bowel obstruction or ileus and may have longer-term ramifications. Reported short-term complication rates vary in the literature due to the inclusion of historical data from retrospective cohort studies with differing proportions of emergency and tertiary centre cases. Clinicians are therefore encouraged to seek up-to-date institutional data when quoting risks. Overall, shorter-term complications of surgery may affect about one third of patients103,106,107. Most can be treated conservatively but 8.4 – 11.3% may require re-operation104,108.Laparoscopic approach appears to be associated with the lowest mortality and morbidity rates compared to open approaches105,109,110. A systematic review103 reported a pooled rate of any **infection** after colectomy as 22% (n=207/938 UC patients; 8 studies). **Surgical site infections** have been reported to occur in 18 – 23%105,108,111and **pneumonia and sepsis** in 8 – 10%105,108.Pooled **wound infection** rates in UC patients who had an elective panproctocolectomy with ileostomy formation (n=11,686) was 6.8 – 14% in a meta-analysis112. **Pelvic infections** have been reported to occur in 5 – 25% of patients who have had a restorative proctocolectomy with IPAA patients and is the commonest cause of pouch failure100,112–118. Data from the largest cohort studies report **anastomotic leak** rates of 3 – 7% and pelvic sepsis rates of 9 – 12%, with the highest rates occurring in patients with Crohn’s disease100,116,117. Studies of IBD patients who have had subtotal colectomy with IRA have shown anastomotic leak rates of 3 – 8%93,119,120. **Small bowel obstruction and ileus** is a common complication after proctocolectomy with either end ileostomy or pouch formation, affecting around 5% in the early post-operative period and 10 – 20% in the longer-term100,103,112,114,116,117,121,122. Most cases are managed conservatively but 25% may require operation123. **Systemic venous thrombosis** has been reported to occur in 3 – 7% of cases112,123,124, with less occurring in elective than emergency cases124.

* 1. **Complications after ileostomy formation:**

Potential longer-term complications associated with end ileostomy formation include skin irritation, retraction, stenosis, prolapse, hernia, and high output. There is a 20 – 30% risk of requiring a re-do operation due to stoma complications over 10 years125,126. A Japanese single-centre study found the cumulative probability of stoma revision surgery to be higher in Crohn’s (29.6% at 10 years) compared to UC (14.5% at 10 years) patients due to disease recurrence and fistula formation125. Many patients consider pouch surgery as a means to avoiding a stoma, but they should be informed that to attenuate the consequences of post-operative anastomotic leak, most centres will still advocate the formation of a diverting loop ileostomy with IPAA. Although this ileostomy is usually temporary, this and the subsequent reversal may be associated with significant morbidity (affecting 10 – 20%)127,128.

* 1. **Sexual function and fecundity:**

The additional pelvic dissection required for proctectomy and pouch formation may result in nerve damage, anatomical changes and formation of scarring and adhesions that lead to sexual dysfunction, reduced fecundity (i.e. the probability of conceiving per month or year of unprotected sexual intercourse) and increased infertility (i.e. inability to conceive after 1 year of unprotected sexual intercourse). When conveying these risks to patients making decisions about surgical management of dysplasia, patient factors (e.g. previous pelvic surgery) and operating surgeon and institutional data should be taken into consideration. They should also be made aware that surgically untreated disease may also be associated with decreased sexual function and fecundity, if medically refractory active inflammation or a cancer were then to develop requiring more extensive resection planes.

1. **Overall sexual dysfunction:** Heterogeneity in the definition of sexual dysfunction, lack of comparison with pre-operative baseline and the inclusion of both open and laparoscopic approaches make it difficult to accurately quantify this risk from the literature available.Meta-analyses114,115 of outcomes after restorative proctocolectomy and IPAA have reported sexual dysfunction rates of 3.0 – 3.6% (n>5000). However, a systematic review129 noted that the majority of more recent observational studies (n=6) published between 2004 and 2014 showed comparable post-operative sexual function scores in proctocolectomy and control groups. Sexual dysfunction may not be long-term, as demonstrated by a Dutch prospective case-control study (n=83) where sexual activity returned to comparable pre-operative levels by 8.5 years of follow-up after proctocolectomy97. No differences in sexual dysfunction have been found when comparing open and laparoscopic-assisted IPAA for UC130–132.
2. **Sexual dysfunction in men:** In the largest case series of male UC patients who had a restorative proctocolectomy and IPAA at the Mayo clinic (n=762)**,** retrograde or no ejaculation was reported by 3% after 10 years and sexual dysfunction was reported in 1% at 1 year and in 2% at 12 years133. Prospective cohort studies using validated sexual function scores have demonstrated improved or no significant change pre and post-proctocolectomy in IBD, although this may be a result of the removal of diseased colon as reflected by corresponding increases in general health-related QOL scores134–137. Post-proctectomy erectile dysfunction more likely occurs in older men (> 50 years old) rather than younger men135,137,138 and is often medically treatable139. Sildenafil completely reversed or satisfactorily improved erectile dysfunction in 79% of post-proctectomy patients (n=32) in a randomised controlled trial139.
3. **Sexual dysfunction in women:** Sexual dysfunction is more difficult to define in women. Older studies have tended to focus on self-reporting of dyspareunia as a marker of sexual dysfunction, which has been shown to increase post-proctectomy and post-IPAA and affect about 8 – 25% of women97,133,140. However, the same studies have shown an increase in overall sexual satisfaction140 and a return to pre-operative baseline levels of sexual activity at 1 year post-proctocolectomy97. More recent studies have incorporated a number of domains including desire, arousal, lubrication, orgasm, satisfaction and pain into a validated Female Sexual Function Index (FSFI). Prospective cohort studies using the FSFI have shown high levels of sexual dysfunction pre- and post-operatively but they tend to improve134,136 or are unchanged135,141 at 6 –12 months follow-up after a proctocolectomy. Again, it is not clear whether the improvements are due to removal of the diseased colorectum. There has been contradictory evidence on whether pouch dysfunction contributes to sexual dysfunction in women142,143.
4. **Fecundity and fertility:** Meta-analyses have demonstrated increased 1-year infertility rates (2 to 5-fold) in UC female patients after proctocolectomy but include low-quality observational studies of mainly open surgery with significant between-study heterogeneity140,144–147. In a meta-analysis145 of 6 studies with patients who were attempting pregnancy, weighted average infertility rates increased from 20% pre-operatively to 63% post-operatively (n=457). Increased use of fertility treatments from 16% pre-IPAA to 51% after IPAA was reported in a systematic review140. The reduced fecundity is believed to be related to scarring and adhesional occlusion of the fallopian tubes from the pelvic dissection. This is supported by the much higher pregnancy success rate reported after in vitro fertilisation and implantation of the embryo directly into the uterus in pouch patients (30%) compared to the reference population (1.3%)148. Small observational studies have suggested better fecundity rates in women after laparoscopic restorative proctocolectomy and IPAA149–151.
   1. **Bowel function and risk of active disease recurrence post-operatively:**
5. **Panproctocolectomy and end ileostomy formation:** UC patients who opt for a panproctocolectomy with complete excision of the rectal mucosa and perineal closure eliminate their risk of future active colitis. Crohn’s patients however still remain at risk of recurrence at non-colorectal sites. The pooled rate of clinical recurrence in the small bowel was 28% overall (95% CI 21.7-35.3; n=260/1004) and 11.5% (95% CI 7.7-16.8) if there was no prior history of ileal disease in a meta-analysis of outcomes after panproctocolectomy in Crohn’s disease126.
6. **Restorative proctocolectomy and IPAA:** 
   1. **Pouch function:** The pouch is meant to act as a reservoir for stool but is inferior to the rectum in its function and so patients should have their expectations managed as to what normal pouch function is. They should expect to open their bowels 3 to 8 times in 24 hours (including 1 to 2 times overnight)112,114.Pouch function appears to improve within the first 5 years after surgery but there appears to be a slight decline over the decades152. **Pouch dysfunction** can occur due to incomplete emptying, urgency, incontinence and pouchitis which can lead to pouch failure. Pooled incidences of mild and severe daytime incontinence have been reported at 14 – 17% and 3.7 – 6.1% respectively in meta-analyses114,115. On average half may require medication (e.g. stool bulking agents, loperamide) to alter their bowel transit152. In a Cleveland clinic cohort (n=1312) a third experienced urgency, 21% wore pads during the day, 26% wore pads at night but 81% had never or rarely experienced incontinence at 10 years post-IPAA117. A systematic review found similar long-term functional outcomes in Crohn’s patients as has been reported for patients with UC153.
   2. **Pouchitis** causes symptoms of stool frequency, urgency and abdominal pain which may require biological therapy or surgical pouch excision for refractory cases154. A prospective Mayo clinic study found a 10-year rate of acute pouchitis of 48% for UC and 59% for Crohn’s patients, and an overall cumulative probability of 81% at 30 years (n=1875)152. Pooled incidence of chronic pouchitis in UC pouch patients was 23% (95% CI 16.5-30.2) in a meta-analysis of 14 studies published after 2001112. PSC patients are also at a higher risk of developing pouchitis155.
   3. **Cuffitis** occurs when the cuff of residual rectal columnar mucosa to which the ileal pouch is anastomosed develops inflammation and rectal bleeding and urgency154. In a single-centre cohort study, cuffitis occurred in 30% (n=119/386) of IBD IPAA who had pouchoscopy for symptoms or surveillance over a median of 4 years156. Reassuringly most respond to topical 5-aminosalicylate or steroid suppositories157.
   4. **Pouch failure** is defined as the formation of a permanent ileostomy, with or without excision of the ﻿pouch and usually occurs due to poor pouch function in addition to septic complications. However, this definition can also include patients who have decided not to reverse their ileostomy because their quality of life with a stoma was better than expected. 10-year pouch failure rates have been reported at 5 – 10% in UC, and up to 37% in Crohn’s patients with peri-anal fistulising and septic complications100,112,114–117,152,153,158. However, a systematic review only looking at patients who had a known pre-operative diagnosis of Crohn’s, rather than de novo Crohn’s diagnosed after IPAA, found a more conservative pouch failure rate of 15%153. Pouch surgery is not contraindicated in selected PSC or Crohn’s patients in some centres78, but it is essential that these patients are counselled very carefully about the higher associated pouch failure rates.
   5. **Strictures at the pouch–anal anastomosis** can cause straining, incomplete evacuation, watery stools and urgency. It has been reported to occur in 9 – 20% of IBD patients by 10 years112,114,117,152,158. The majority respond to digital or graduated Hegar’s dilatation117 but more refractory strictures may require surgical intervention123.
7. **Subtotal colectomy and ileorectal anastomosis (IRA):** 
   1. **Normal rectal function** after IRA is altered due to functional changes159. Reported median bowel movement frequency is 4 to 6 times during the day and none or once at night93. Nocturnal seepage/incontinence reportedly affects 0 – 8% and urgency affects 20 – 68%93.﻿ ﻿Two single-centre studies found similar HRQOL in UC IPAA and IRA patients but the IRA group demonstrated less bowel frequency (median 5-6 vs. 7) and greater urgency98,159.
   2. **Risk of proctitis recurrence** requiring treatment (usually topical 5-aminosalicylates) after IRAhas been reported as between 9 – 76.9%93,95,98,160. The variation is likely related to discrepancies in the length of recto-sigmoid left in situ and follow-up durations. Proctitis developed in UC patients post-IRA in 76.9% over mean follow-up of 5.4 years in a Swedish single-centre study (n=101 UC patients)95 and 28% over median follow-up of 9 years in a Cleveland clinic study (n=86 UC patients)98. The cumulative risk of Crohn’s recurrence has been reported as 43% at 5 years and 67% at 10 years161. Subtotal colectomy and IRA was associated with a 3-fold higher risk of Crohn’s recurrence than proctocolectomy even when only studies in the era since the introduction of biological therapy were included in a meta-analysis (OR 3.23, 95% CI 1.62–6.44, *p*<0.001)94.
   3. **IRA survival** (avoidance of a proctectomy): Cumulative rates have been reported at 63 – 76% at 10 years95,98,120,160,162 and 46 – 60% at 20 years98,162. The main reasons for a completion proctectomy after an IRA are proctitis, poor function or neoplasia developing in the rectum. Pouch survival following IRA does not appear to be affected if there is delayed completion proctectomy163.
8. **Segmental colectomy and primary anastomosis:** Risk ofCrohn’s colitis recurrence after segmental colectomy,requiringa re-operation has been reported at 27 – 31% after approximately 15 years’ follow-up in the largest cohort studies164,165. A meta-analysis of 11 studies demonstrated no significant difference in surgical Crohn’s disease recurrence between those who had subtotal colectomy (n=510) and segmental colectomy (n=500)94. There are less data on the risk ofUC recurrenceafter segmental colectomy. In a multi-centre retrospective cohort study of UC patients with mainly left sided disease, who had a segmental colectomy performed for reasons other than active colitis (e.g. neoplasia or colonic stenosis), 49.3% (n=34/69) developed clinical UC recurrence after follow-up of a median of 3.3 years, and 20.3% required re-operation after a median delay of 19 months due to refractory colitis96.
   1. **Health-related quality of life (HRQOL):**

OverallHRQOLhas been found to be high and comparable in longer term follow up studies of panproctocolectomy with end ileostomy versus restorative proctocolectomy with IPAA166,167. Some HRQOL domain/item-specific differences have been observed in end ileostomy patients, including lower body image satisfaction166,168,169, less dietary restriction169 and conflicting results for the impact on social/work functioning168,170,171. However, interpretation is limited by small sample sizes, limited follow-up, heterogeneity in the tools used to measure HRQOL and a more comorbid population opting for end ileostomy formation over a pouch. Longer-term single centre follow up studies have suggested good longitudinal HRQOL after pouch surgery117,152. After 10 years, on average only 12% reported any social, work or sexual restrictions and 24% reported any dietary restrictions in the Cleveland clinic study, with no significant differences between UC (n=1312), Crohn’s and FAP patients117. After 30 years post-pouch surgery at the Mayo clinic, minor restrictions in their diet, travel, and recreation were reported by 46%, 34%, and 31% of IBD patients respectively but 82% did not think that their work was affected and 95% did not report any severe restrictions on their recreational activities152. It should be borne in mind when counselling patients, that the high post-operative HRQOLs observed in these studies may have been driven by removal of the inflamed colon which may not be relevant to a dysplasia cohort in clinical remission112,172.

* 1. **Risk of post-operative cancer:**

1. **Pouch cancers:** Most pouch cancer arise from retained rectal cuff but the overall risk of a pouch adenocarcinoma is low (<1.5% at 10 years)173,174. However, the risk is substantially elevated (9 to 15-fold) in colitis patients with prior colonic neoplasia173,175–177. In meta-analyses including around 5000 IPAA patients, pouch cancers were more likely in those with a previous history of colorectal cancer (OR 15.0; 95% CI 6.6–34.5; n=5216)173, dysplasia (OR 4.4; 95% CI 1.9–10.1)173, or any colonic neoplasia (OR, 8.8; 95% CI, 4.6–16.8)175. It is therefore recommended that patients who have pouch surgery for dysplasia, have annual endoscopic pouch surveillance post-operatively9–11. In a small prospective Dutch single-centre study of IBD IPAA patients (n=44) who had neoplasia detected in their colectomy specimens followed by chromoendoscopy pouch surveillance, only 2 (4.5%) developed LGD after a median of 8.6 years which could be endoscopically managed and none developed pouch cancers177. In a single centre cohort study of 440 UC IPAA patients who had a pre-operative diagnosis of dysplasia, only 4 (0.9%) developed pouch cancers over the mean 10 years of follow-up176.
2. **Rectal cancer after colectomy and IRA:** The overall pooled prevalence for post-IRA UC patients was 1.6% (95% CI 0.8–2.6%) in a meta-analysis of studies published after 1990173. The absolute cumulative risk has been reported as 0 – 0.3% at 5-years, 0 – 2% at 10-years and 2 – 14% at 20-years follow-up95,98,174. Subanalysis of patients with pre-operative dysplasia diagnoses is often not performed, however. The risk of rectal cancer was 15-fold higher than the general population (standardised incidence ratio 15.3; 95% CI 3.8-61.3) in a Swedish population based cohort study of post-IRA UC patients who had a pre-operative diagnosis of dysplasia (n=1112)174. The cumulative incidence of rectal cancer was 25% after 10 years’ follow-up (95% CI 0.4–57.4) in a French multi-centre study of post-IRA UC patients who also had pre-operative dysplasia (n=343)178. Data on the risk of post-IRA rectal cancer in Crohn’s patients are limited by much smaller studies which have included pre-operative cancer diagnoses. In a case series of Crohn’s patients who had a subtotal or segmental colectomy for pre-operative dysplasia and followed up for a median 6 years**,** one patient (9%; n=1/11) who had not complied with surveillance developed a rectal cancer53. In another case series of Crohn’s patients who had an IRA for pre-operative cancer diagnoses, 35% (n=6/17) developed metachronous rectal cancer within a median follow-up of 6.8 years despite most (85%) having annual surveillance179. Patients should be advised that annual endoscopic surveillance of the rectum will still be required after a colectomy and IRA for dysplasia. If a rectal cancer were to develop and a completion proctectomy and IPAA surgery were performed, the effect of neoadjuvant or adjuvant radiotherapy has been reported in a very small case series of UC patients (n<10) to be associated with increased pouch failure rates due to radiation injury or cancer recurrence or progression180–182.
3. **Rectal cancer in a non-anastomosed rectal stump:** The risk appears to be low173,174,183, but it is significantly increased if there was a pre-operative diagnosis of colorectal neoplasia174,183; by a 22-fold increase compared to the general population [SIR 21.7 (95% CI 3.1-153.9)] in a Swedish population-based cohort study174 or 4-fold compared to IBD patients without pre-operative neoplasia [HR 3.8 (95% CI 1.07–13.53)] in a Dutch single-centre cohort study183. Therefore, leaving a rectal stump in situ long-term is not recommended in the context of a dysplasia diagnosis.
4. **Colorectal cancer after segmental colectomy:** Historical studies have demonstrated high (approximately 40%) risks of synchronous neoplasia at colonic sites distant to the pre-operatively detected neoplasia50,53,184,185. However, more recent studies reflecting modern surveillance and high definition endoscopic imaging practices suggest that the true synchronous rates are much lower than initially reported4,186. Reported rates of metachronous neoplasia if segmental colectomy has been performed for cancer, have varied from 0 – 40% over a 7-year surveillance follow-up period with the highest incidences occurring in patients who pre-operatively had cancer rather than dysplasia96,179,187–189. In a small Chicago case series of IBD patients (n=17) with confirmed neoplasia and quiescent disease in the distal colon who underwent segmental or subtotal colectomy with IRA and had follow-up with two high-definition colonoscopies over a median 17 months, no patients developed advanced neoplasia in the remaining colon; although 2 patients required completion proctectomy for metachronous endoscopically unresectable LGD188.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**SUPPORTING DECISION-MAKING POST-CONSULTATION**

Expert guidance on obtaining consent and shared decision-making recommends that sufficient time and additional resources are provided to the patient whilst they deliberate and consider their values and wishes, including facilitating a second opinion if sought by the patient14,15,70,76. Eighty percent of the DECIDE patient stakeholders greatly valued being given time after their initial consultations to independently investigate their options by reading literature and speaking to specialist nurses or other patients (Supplementary Appendices 2). The gains in knowledge and autonomy resulting from this process reduced their anxiety and hesitancy in making a decision.

**Visual decision aids** were considered to be important decision-making facilitators by the DECIDE patient stakeholders and the independent decision-making expert in view of the potentially overwhelming amount of technical details about the management options and the risk information that needs to be conveyed. Paper and web-based visual aids have been shown to facilitate confident decision-making in IBD patients choosing between surgical and/or medical options for symptomatic IBD190–192. None are specifically relevant for dysplasia with asymptomatic colitis and so we have developed a new patient-facing decision aid to help support decision-making (Supplementary Appendices 4). Patients considering surgery should be signposted to **patient support groups or charities**. The majority (80%) of the DECIDE patient stakeholders and other qualitative research indicates that patients strongly value the opportunity to speak to other patients about their lived experiences with a pouch or stoma and to answer the questions that health professionals cannot21,63,66,74. In the UK, organisations such as Ileostomy & Internal Pouch Association (https://iasupport.org/) can provide contact details for trained patient volunteers, including those who have had a proctocolectomy for IBD with or without dysplasia. **Nurse specialists in IBD and/or pouch and stoma care** play an important role in counselling by providing patient-centred information, emotional and practical support, managing expectations and providing reassurance to patients193,19474 (Supplementary Appendices 2). An opportunity to meet with a specialist nurse should be offered after the initial medical-surgical consultation and may take place on the same day depending on local resources.

Often patients wish to consolidate their views and have an opportunity to ask further questions with a known clinician at a **second consultation** before they agree on an informed preference-based management option14,15,70. Several of the DECIDE patient stakeholders revealed that the emotional impact of being given a pre-cancerous or high cancer risk diagnosis hindered information retention at their initial consultation with the gastroenterologist or surgeon (Supplementary Appendices 2). A lack of continuity of clinician care and limitations on the consultation appointment time were cited as barriers to patient engagement in shared decision-making and satisfaction with their care. However, if a patient defers the decision for a significant length of time e.g. more than 6 months, a repeat endoscopy to ensure no advanced neoplasia progression should be offered.

**CONCLUSION**

By consolidating evidence for best practice using literature review, key stakeholder and decision-making expert consultation, we have developed international consensus recommendations to support healthcare professionals counselling patients on the management of high cancer risk colitis-associated dysplasia. The final toolkit includes clinician and patient decision aids to facilitate shared decision-making. Review of the literature highlights the need for further prospective studies to better inform what the long-term cancer risk is for invisible dysplasia and after resection of dysplasia by either ESD or less extensive colectomy.

**REFERENCES**

1. Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. *Inflamm Bowel Dis*. 2013;19(4):789-799. doi:10.1097/MIB.0b013e31828029c0

2. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. *Lancet*. 2020;395(10218):123-131. doi:10.1016/S0140-6736(19)32545-0

3. Kabir M, Thomas-Gibson S, Hart AL, Wilson A. Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace results of an international clinician survey. *J Crohn’s Colitis*. 2022;16(1):39-48. doi:10.1093/ecco-jcc/jjab110

4. Kabir M, Fofaria R, Arebi N, et al. Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). *Aliment Pharmacol Ther*. 2020;52(July):5-9. doi:10.1111/apt.15778

5. Baars JE, Siegel CA, van’t Spijker A, Markus T, Kuipers EJ, van der Woude CJ. Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. *Dig Liver Dis*. 2010;42(11):777-784. doi:10.1016/j.dld.2010.03.023

6. Siegel CA, Schwartz LM, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. *Inflamm Bowel Dis*. 2010;16(10):1658-1662. doi:10.1002/ibd.21233

7. Awais D, Swaminath AC, Velayos FS, et al. S1141 Colon Cancer Risk Perception in Ulcerative Colitis: Patients Overestimate the Risk, But Disagree with the Therapy. *Gastroenterology*. 2009;136(5):A-198-A-199. doi:10.1016/S0016-5085(09)60890-8

8. Kabir M, Thomas-Gibson S, Hart AL, et al. Management of inflammatory bowel disease associated colonic dysplasia: factors predictive of patient choice and satisfaction. *Color Dis*. 2021;23(4):882-893. doi:10.1111/codi.15460

9. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in in fl ammatory bowel disease. *Gastrointest Endosc*. 2015;81(3):489-501. doi:10.1016/j.gie.2014.12.009

10. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *J Crohn’s Colitis*. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008

11. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut*. September 2019:gutjnl-2019-318484. doi:10.1136/gutjnl-2019-318484

12. Brown SR, Fearnhead NS, Faiz OD, et al. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. *Color Dis*. 2018;20(Supplement 8):3-117. doi:http://dx.doi.org/10.1111/codi.14448

13. Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. *Gut*. 2012;61(3):459-465. doi:10.1136/gutjnl-2011-300988

14. Legare F, Moumjid-Ferdjaoui N, Drolet D, et al. Core competencies for shared decision making training programs: insights from an international, interdisciplinary working group. *J Contin Educ Health Prof*. 2013;33(4):267-273. doi:10.1002/chp.21197.Core

15. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: A model for clinical practice. *J Gen Intern Med*. 2012;27(10):1361-1367. doi:10.1007/s11606-012-2077-6

16. Friedman S, Cheifetz AS, Farraye FA, et al. Doctor message can alter patients’ behavior and attitudes regarding inflammatory bowel disease and colon cancer. *Inflamm Bowel Dis*. 2012;18(8):1531-1539. doi:10.1002/ibd.21861

17. Burr NE, Derbyshire E, Taylor J, et al. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. *BMJ*. 2019;367:l6090. doi:10.1136/bmj.l6090

18. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. www.guideline development.org/handbook. Published 2013. Accessed November 5, 2019.

19. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. *CMAJ*. 2010;182(18):E839-42. doi:10.1503/cmaj.090449

20. Braun V, Clarke V. *Successful Qualitative Research: A Practical Guide for Beginners*.; 2013. http://eprints.uwe.ac.uk/21156/3/SQR Chap 1 Research Repository.pdf. Accessed May 14, 2018.

21. Kabir M, Thomas-gibson S, Hart A, Wilson A. Factors affecting patient decision-making in inflammatory bowel disease ( IBD ) dysplasia management : a mixed methods study. *Gut*. 2019;68(Suppl 2):4. doi:10.1136/gutjnl-2019-bsgabstracts.155

22. Brown BB. Delphi process: a methodology used for the elicitation of opinions of experts. Santa Monica, CA: RAND Corporation. https://www.rand.org/pubs/papers/P3925.html. Published 1968. Accessed September 1, 2020.

23. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohn’s Colitis*. 2013;7(12):982-1018. doi:10.1016/j.crohns.2013.09.016

24. Wanders LK, Dekker E, Pullens B, Bassett P, Travis SPL, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: A meta-analysis. *Clin Gastroenterol Hepatol*. 2014;12(5):756-764. doi:10.1016/j.cgh.2013.07.024

25. Curtius K, Kabir M, Al Bakir I, et al. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. *Gut*. 2022;705-715:705-715. doi:10.1136/gutjnl-2020-323546

26. Alkandari A, Thayalasekaran S, Bhandari M, et al. Endoscopic resections in inflammatory bowel disease: A multicentre european outcomes study. *J Crohn’s Colitis*. 2019;13(11):1394-1400. doi:10.1093/ecco-jcc/jjz075

27. Soetikno R, East J, Suzuki N, et al. Endoscopic submucosal dissection for nonpolypoid colorectal dysplasia in patients with inflammatory bowel disease: in medias res. *Gastrointest Endosc*. 2018;87(4):1085-1094. doi:10.1016/j.gie.2018.01.013

28. Macken E, Van Dongen S, De Brabander I, Francque S, Driessen A, Van Hal G. Post-colonoscopy colorectal cancer in Belgium: characteristics and influencing factors. *Endosc Int open*. 2019;7(5):E717-E727. doi:10.1055/a-0751-2660

29. Puli SR, Kakugawa Y, Gotoda T, Antillon D, Saito Y, Antillon MR. Meta-analysis and systematic review of colorectal endoscopic mucosal resection. *World J Gastroenterol*. 2009;15(34):4273-4277. doi:10.3748/wjg.15.4273

30. Geraghty J, O’Toole P, Anderson J, Valori R, Sarkar S. National survey to determine current practices, training and attitudes towards advanced polypectomy in the UK. *Frontline Gastroenterol*. 2015;6(2):85-93. doi:10.1136/flgastro-2014-100516

31. Gulati S, Emmanuel A, Burt M, Dubois P, Hayee B, Haji A. Outcomes of Endoscopic Resections of Large Laterally Spreading Colorectal Lesions in Inflammatory Bowel Disease: a Single United Kingdom Center Experience. *Inflamm Bowel Dis*. 2018;24(6):1196-1203. doi:https://dx.doi.org/10.1093/ibd/izx113

32. Matsumoto K, Oka S, Tanaka S, et al. Long-term outcomes after endoscopic submucosal dissection for ulcerative colitis-associated dysplasia. *Digestion*. 2019. doi:10.1159/000503341

33. Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. *Gastroenterology*. 2021;161(3):1043-1051.e4. doi:10.1053/j.gastro.2021.05.063

34. Morar P, Read J, Arora S, et al. Research: Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study. *Frontline Gastroenterol*. 2015;6(4):290. doi:10.1136/FLGASTRO-2014-100549

35. Morar PS, Sevdalis N, Warusavitarne J, et al. Establishing the aims, format and function for multidisciplinary team-driven care within an inflammatory bowel disease service: a multicentre qualitative specialist-based consensus study. *Frontline Gastroenterol*. 2018;9(1):29-36. doi:10.1136/flgastro-2017-100835

36. Kapasi R, Glatter J, Lamb CA, et al. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. *Frontline Gastroenterol*. 2020;11(3):178-187. doi:10.1136/flgastro-2019-101260

37. Louis E, Dotan I, Ghosh S, Mlynarsky L, Reenaers C, Schreiber S. Optimising the Inflammatory Bowel Disease Unit to Improve Quality of Care: Expert Recommendations: Table 1. *J Crohn’s Colitis*. 2015;9(8):685-691. doi:10.1093/ecco-jcc/jjv085

38. Leong RWL, Perry J, Campbell B, et al. Knowledge and predictors of dysplasia surveillance performance in inflammatory bowel diseases in Australia. *Gastrointest Endosc*. 2015;82(4):708-714. doi:10.1016/j.gie.2015.04.004

39. Choi CHR, Bakir I Al, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. *Nat Rev Gastroenterol Hepatol*. 2017;14(4):218-229. doi:10.1038/nrgastro.2017.1

40. Baker AM, Cross W, Curtius K, et al. Evolutionary history of human colitis-associated colorectal cancer. *Gut*. 2019;68(6):985-995. doi:10.1136/gutjnl-2018-316191

41. Sanduleanu S, Rutter MD. Interval colorectal cancers in inflammatory bowel disease: The grim statistics and true stories. *Gastrointest Endosc Clin N Am*. 2014;24(3). doi:10.1016/j.giec.2014.03.001

42. Sebastian S, Hernández V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). *J Crohn’s Colitis*. 2014;8(1):5-18. doi:10.1016/j.crohns.2013.04.008

43. Choi C ho R, Ignjatovic-Wilson A, Askari A, et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. *Am J Gastroenterol*. 2015;110(10):1461-1472. doi:10.1038/ajg.2015.248

44. Fumery M, Dulai PS, Gupta S, et al. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2017;15(5):665-674.e5. doi:https://dx.doi.org/10.1016/j.cgh.2016.11.025

45. Shah SC, ten Hove JR, Castaneda D, et al. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2018;16(7):1106. doi:http://dx.doi.org/10.1016/j.cgh.2018.01.023

46. Cremer A, Demetter P, De Vos M, et al. Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia. *Clin Gastroenterol Hepatol*. 2020;18(7):1528-1536. doi:10.1016/j.cgh.2019.05.062

47. De Jong ME, Van Tilburg SB, Nissen LHC, et al. Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. *J Crohns Colitis*. 2019;13(12):1485-1491. doi:10.1093/ecco-jcc/jjz114

48. Velayos F, Loftus Jr. E, Jess T, et al. Predictive and Protective Factors Associated With Colorectal Cancer in Ulcerative Colitis: A Case-Control Study. *Gastroenterology*. 2006;130(7):1941-1949. doi:http://dx.doi.org/10.1053/j.gastro.2006.03.028

49. Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. *Gastroenterology*. 2001;120(6):1356-1362. doi:10.1053/gast.2001.24052

50. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? *Lancet*. 1994;343(8889):71-74. doi:10.1016/S0140-6736(94)90813-3

51. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. *Gastroenterology*. 1994;107(4):934-944. doi:10.1016/0016-5085(94)90216-X

52. Kiran RP, Ahmed Ali U, Nisar PJ, et al. Risk and Location of Cancer in Patients With Preoperative Colitis-Associated Dysplasia Undergoing Proctocolectomy. *Ann Surg*. 2014;259(2):302-309. doi:10.1097/SLA.0b013e31828e7417

53. Kiran RP, Nisar P, Goldblum JR, et al. Dysplasia associated with Crohn’s colitis: Segmental colectomy or more extended resection? *Ann Surg*. 2012;256(2):221-226. doi:http://dx.doi.org/10.1097/SLA.0b013e31825f0709

54. Murphy J, Kalkbrenner KA, Pemberton JH, et al. Dysplasia in ulcerative colitis as a predictor of unsuspected synchronous colorectal cancer. *Dis Colon Rectum*. 2014;57(8):993-998. doi:http://dx.doi.org/10.1097/DCR.0000000000000172

55. Olecki EJ, Perez Hoguin RA, King S, Razavi N, Scow JS. High-Grade Dysplasia in Inflammatory Bowel Disease. *Dis Colon Rectum*. December 2021. doi:10.1097/DCR.0000000000002242

56. Lightner AL, Vogler S, McMichael J, et al. Dysplastic progression to adenocarcinoma is equivalent in ulcerative colitis and crohn’s disease. *J Crohn’s Colitis*. 2021;15(1):24-34. doi:10.1093/ecco-jcc/jjaa133

57. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: Cancer risk of low-grade dysplasia in chronic ulcerative colitis. *Aliment Pharmacol Ther*. 2007;25(6):657-668. doi:10.1111/j.1365-2036.2007.03241.x

58. Ten Hove JR, Mooiweer E, van der Meulen de Jong AE, Dekker E, Ponsioen CY, Siersema PD. Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: A retrospective study comparing chromoendoscopy and white-light endoscopy. *Endoscopy*. 2017;49(2):161-168. doi:http://dx.doi.org/10.1055/s-0042-119394

59. Kandiah K, Subramaniam S, Thayalasekaran S, et al. Multicentre randomised controlled trial on virtual chromoendoscopy in the detection of neoplasia during colitis surveillance high-definition colonoscopy (the VIRTUOSO trial). *Gut*. 2021;70(9):1684-1690. doi:10.1136/gutjnl-2020-320980

60. Westwood N, Travis SPL. Review article: What do patients with inflammatory bowel disease want for their clinical management? *Aliment Pharmacol Ther*. 2008;27(SUPPL. 1):1-8. doi:10.1111/j.1365-2036.2008.03605.x

61. Tulchinsky H, Dotan I, Alper A, et al. Comprehensive Pouch Clinic Concept for Follow-Up of Patients After Ileal Pouch Anal Anastomosis: Report of 3 Years’ Experience in a Tertiary Referral Center Background: We designed and evaluated a novel concept in. 2008. doi:10.1002/ibd.20430

62. Lai C, Sceats LA, Qiu W, Park KT, Morris AM, Kin C. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. *Color Dis*. 2019;21(12):1406-1414. doi:10.1111/codi.14759

63. Dibley L, Czuber-Dochan W, Wade T, et al. Patient Decision-Making About Emergency and Planned Stoma Surgery for IBD: A Qualitative Exploration of Patient and Clinician Perspectives. *Inflamm Bowel Dis*. 2018;24(2):235-246. doi:10.1093/ibd/izx043

64. Mui M, An V, Lovell J, D’Souza B, Woods R. Patients’ perspective on bowel resection for inflammatory bowel disease. *Int J Colorectal Dis*. 2018;33(2):219-222. doi:10.1007/s00384-017-2941-2

65. Spinelli A, Carvello M, Adamina M, et al. Patients’ perceptions of surgery for inflammatory bowel disease. *Color Dis*. 2021;23(10):2690-2698. doi:10.1111/codi.15813

66. Cohan JN, Ozanne EM, Hofer RK, et al. Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. *BMC Gastroenterol*. 2021;21(1):347. doi:10.1186/s12876-021-01916-0

67. Siegel CA, Lofland JH, Naim A, et al. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making. *Patient - Patient-Centered Outcomes Res*. 2016;9(1):79-89. doi:10.1007/s40271-015-0126-z

68. Baars JE, Markus T, Kuipers EJ, Van Der Woude CJ. Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: Results from a patient-empowerment study. *Digestion*. 2010;81(2):113-119. doi:10.1159/000253862

69. Rubin DT, Hart A, Panaccione R, et al. Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. *Inflamm Bowel Dis*. October 2020. doi:10.1093/ibd/izaa257

70. Elwyn G, Durand MA, Song J, et al. A three-talk model for shared decision making: Multistage consultation process. *BMJ*. 2017;359. doi:10.1136/bmj.j4891

71. Elwyn GJ, Edwards A, Kinnersley P, Grol R. Shared decision making and the concept of equipoise: The competences of involving patients in healthcare choices. *Br J Gen Pract*. 2000;50(460):892-897. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1313854/pdf/11141876.pdf. Accessed May 21, 2018.

72. Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: A systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. *Patient Educ Couns*. 2014;94(3):291-309. doi:10.1016/j.pec.2013.10.031

73. Louis E, Ramos-Goñi JM, Cuervo J, et al. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. *Patient - Patient-Centered Outcomes Res*. 2020;13(3):317-325. doi:10.1007/s40271-019-00407-5

74. Baker DM, Lee MJ, Jones GL, Brown SR, Lobo AJ. The Informational Needs and Preferences of Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study. *Inflamm Bowel Dis*. 2018;24(1):179-190. doi:10.1093/ibd/izx026

75. Department of Health. Reference guide to consent for examination or treatment Second edition. Department of Health. www.dh.gov.uk/consent. Published 2009. Accessed August 24, 2020.

76. Royal College of Surgeons of England. Consent: Supported Decision-Making. Good Practice Guides. https://www.rcseng.ac.uk/standards-and-research/standards-and-guidance/good-practice-guides/. Published 2016. Accessed November 3, 2020.

77. Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. *J Crohns Colitis*. 2015;9(1):4-25. doi:10.1016/j.crohns.2014.08.012

78. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. *J Crohn’s Colitis*. 2020;14(2):155-168. doi:10.1093/ecco-jcc/jjz187

79. Ryhlander J, Ringstrom G, Simrén M, Stotzer P-O, Jakobsson S. Undergoing repeated colonoscopies – experiences from patients with inflammatory bowel disease. *Scand J Gastroenterol*. 2019;54(12):1467-1472. doi:10.1080/00365521.2019.1698649

80. Rutter MD, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible Costs and Benefits of Ulcerative Colitis Surveillance: A Patient Survey. *Dis Colon Rectum*. 2006;49(8):1177-1183. doi:10.1007/s10350-006-0546-x

81. Oxelmark L, Nordström G, Sjöqvist U, Löfberg R. Anxiety, functional health status, and coping ability in patients with ulcerative colitis who are undergoing colonoscopic surveillance. *Inflamm Bowel Dis*. 2004;10(5):612-617. doi:10.1097/00054725-200409000-00017

82. Burke KE, Nayor J, Campbell EJ, Ananthakrishnan AN, Khalili H, Richter JM. Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. *Dig Dis Sci*. 2020;65(1):111-118. doi:10.1007/s10620-019-05754-9

83. Stjärngrim J, Ekbom A, Hammar U, Hultcrantz R, Forsberg AM. Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population? *Gut*. 2019;68(9):1588-1596. doi:10.1136/gutjnl-2018-316651

84. Wintjens DSJ, Bogie RMM, van den Heuvel TRA, et al. Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study. *J Crohn’s Colitis*. 2018;12(7):777-783. doi:10.1093/ecco-jcc/jjy044

85. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, et al. Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance. *Clin Gastroenterol Hepatol*. 2015;13(9):1656-1661. doi:http://dx.doi.org/10.1016/j.cgh.2015.04.183

86. Ahmad A, Dhillon A, Saunders BP, Kabir M, Thomas-Gibson S. Validation of post-colonoscopy colorectal cancer (PCCRC) cases reported at national level following local root cause analysis: REFLECT study. *Frontline Gastroenterol*. 2022;0:flgastro-2021-102016. doi:10.1136/flgastro-2021-102016

87. Bye WA, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colon cancer in patients with inflammatory bowel disease. *Cochrane Database Syst Rev*. 2017;(9). doi:10.1002/14651858.CD000279.pub4

88. Arezzo A, Passera R, Marchese N, Galloro G, Manta R, Cirocchi R. Systematic review and meta-analysis of endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal lesions. *United Eur Gastroenterol J*. 2016;4(1):18-29. doi:10.1177/2050640615585470

89. Mohapatra S, Sankaramangalam K, Lopimpisuth C, et al. Advanced endoscopic resection for colorectal dysplasia in inflammatory bowel disease: a meta-analysis. *Endosc Int Open*. 2022;10(05):E593-E601. doi:10.1055/a-1784-7063

90. Ross H, Steele SR, Varma M, et al. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum*. 2014;57(1):5-22. doi:10.1097/DCR.0000000000000030

91. Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn’s Disease. *Dis Colon Rectum*. 2020:1028-1052. doi:10.1097/DCR.0000000000001716

92. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn’s Disease. *J Crohn’s Colitis*. 2017;12(1):1-16. doi:10.1093/ecco-jcc/jjx061

93. Scoglio D, Ali UA, Fichera A. Surgical treatment of ulcerative colitis: Ileorectal vs ileal pouch-anal anastomosis. *World J Gastroenterol*. 2014;20(37):13211-13218. doi:10.3748/wjg.v20.i37.13211

94. Angriman I, Pirozzolo G, Bardini R, Cavallin F, Castoro C, Scarpa M. A systematic review of segmental vs subtotal colectomy and subtotal colectomy vs total proctocolectomy for colonic Crohn’s disease. *Color Dis*. 2017;19(8):e279-e287. doi:10.1111/codi.13769

95. Andersson P, Norblad R, Soderholm JD, Myrelid P. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis--a single institution experience. *J Crohns Colitis*. 2014;8(7):582-589. doi:https://dx.doi.org/10.1016/j.crohns.2013.11.014

96. Frontali A, Cohen L, Bridoux V, et al. Segmental Colectomy for Ulcerative Colitis: Is There a Place in Selected Patients Without Active Colitis? An International Multicentric Retrospective Study in 72 Patients. *J Crohn’s Colitis*. June 2020. doi:10.1093/ecco-jcc/jjaa107

97. Doeksen A, Gooszen JAH, van Duijvendijk P, et al. Sexual and urinary functioning after rectal surgery: a prospective comparative study with a median follow-up of 8.5 years. *Int J Colorectal Dis*. 2011;26(12):1549-1557. doi:10.1007/s00384-011-1288-3

98. Da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. *Br J Surg*. 2010;97(1):65-69. doi:10.1002/bjs.6809

99. Olsen K, Juul S, Bülow S, et al. Female fecundity before and after operation for familial adenomatous polyposis. *Br J Surg*. 2003;90(2):227-231. doi:10.1002/bjs.4082

100. ACPGBI Ileoanal pouch report. Ileoanal pouch report 2017. https://www.acpgbi.org.uk/content/uploads/2016/07/Ileoanal-Pouch-Report-2017-FINAL.compressed.pdf. Published 2017. Accessed September 24, 2020.

101. Deputy M, Worley G, Patel K, et al. Long-term outcome and quality of life after continent ileostomy for ulcerative colitis: A systematic review. *Colorectal Dis*. 2021;23(9):2286-2299. doi:10.1111/codi.15788

102. Singh S, Al-Darmaki A, Frolkis AD, et al. Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. *Gastroenterology*. 2015;149(4):928-937. doi:10.1053/j.gastro.2015.06.001

103. Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. *Aliment Pharmacol Ther*. 2016;44(8):807-816. doi:10.1111/apt.13763

104. Rahal MA, Karaoui WR, Mailhac A, Tamim H, Shaib Y. Surgical outcomes among inflammatory bowel disease patients undergoing col-ectomy : results from a national database. *Acta Gastroenterol Belg*. 2018;Vol. LXXXI. https://www.facs.org/quality-programs/. Accessed September 29, 2020.

105. Causey MW, Stoddard D, Johnson EK, et al. Laparoscopy impacts outcomes favorably following colectomy for ulcerative colitis: a critical analysis of the ACS-NSQIP database. *Surg Endosc*. 2013;27(2):603-609. doi:10.1007/s00464-012-2498-7

106. de Silva S, Ma C, Proulx M, et al. Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2011;9(11):972-980. doi:10.1016/j.cgh.2011.07.016

107. Kulaylat AS, Kulaylat AN, Schaefer EW, et al. Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. *JAMA Surg*. 2017;152(8):e171538. doi:10.1001/jamasurg.2017.1538

108. Loftus E V, Friedman HS, Delgado DJ, Sandborn WJ. Colectomy subtypes, follow-up surgical procedures postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. *Inflamm Bowel Dis*. 2009;15(4):566-575. doi:10.1002/ibd.20810

109. Fleming FJ, Francone TD, Kim MJ, Gunzler D, Messing S, Monson JRT. A Laparoscopic Approach Does Reduce Short-Term Complications in Patients Undergoing Ileal Pouch-Anal Anastomosis. *Dis Colon Rectum*. 2011;54(2):176-182. doi:10.1007/DCR.0b013e3181fb4232

110. Bartels SAL, Gardenbroek TJ, Ubbink DT, Buskens CJ, Tanis PJ, Bemelman WA. Systematic review and meta-analysis of laparoscopic versus open colectomy with end ileostomy for non-toxic colitis. *Br J Surg*. 2013;100(6):726-733. doi:10.1002/bjs.9061

111. Bhakta A, Tafen M, Glotzer O, et al. Increased Incidence of Surgical Site Infection in IBD Patients. *Dis Colon Rectum*. 2016;59(4):316-322. doi:10.1097/DCR.0000000000000550

112. Baker DM, Folan AM, Lee MJ, Jones GL, Brown SR, Lobo AJ. A systematic review and meta-analysis of outcomes after elective surgery for ulcerative colitis. *Color Dis*. September 2020:codi.15301. doi:10.1111/codi.15301

113. Sahami S, Bartels SAL, D’Hoore A, et al. A Multicentre Evaluation of Risk Factors for Anastomotic Leakage After Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease. *J Crohn’s Colitis*. 2016;10(7):773-778. doi:10.1093/ecco-jcc/jjv170

114. Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJHM. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. *Dig Surg*. 2005;22(1-2):69-79. doi:10.1159/000085356

115. De Zeeuw S, Ali UA, Donders RART, Hueting WE, Keus F, Van Laarhoven CJHM. Update of complications and functional outcome of the ileo-pouch anal anastomosis: Overview of evidence and meta-analysis of 96 observational studies. *Int J Colorectal Dis*. 2012;27(7):843-853. doi:10.1007/s00384-011-1402-6

116. Worley GHT, Fearnhead NS, Brown SR, Acheson AG, Lee MJ, Faiz OD. Review of current practice and outcomes following ileoanal pouch surgery: lessons learned from the Ileoanal Pouch Registry and the 2017 Ileoanal Pouch Report. *Color Dis*. 2018;20(10):913-922. doi:10.1111/codi.14316

117. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: Analysis of outcome and quality of life in 3707 patients. *Ann Surg*. 2013;257(4):679-685. doi:10.1097/SLA.0b013e31827d99a2

118. Mark-Christensen A, Kjær MD, Ganesalingam S, et al. Increasing Incidence of Pelvic Sepsis Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis in Denmark. *Dis Colon Rectum*. 2019;62(8):965-971. doi:10.1097/DCR.0000000000001404

119. Duclos J, Lefevre JH, Lefrancois M, et al. Immediate outcome, long-term function and quality of life after extended colectomy with ileorectal or ileosigmoid anastomosis. *Colorectal Dis*. 2014;16(8):O288-96. doi:https://dx.doi.org/10.1111/codi.12558

120. O’Riordan JM, O’Connor BI, Huang H, et al. Long-term outcome of colectomy and ileorectal anastomosis for Crohn’s colitis. *Dis Colon Rectum*. 2011;54(11):1347-1354. doi:10.1097/DCR.0b013e31822c9b2d

121. Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. *Color Dis*. 2013;15(9):1123-1129. doi:10.1111/codi.12267

122. Mege D, Colombo F, Stellingwerf ME, et al. Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease: A multivariate analysis in four expert centres in Europe. *J Crohn’s Colitis*. 2019;13(3):294-301. doi:10.1093/ecco-jcc/jjy160

123. Sagar PM, Pemberton JH. Intraoperative, postoperative and reoperative problems with ileoanal pouches. *Br J Surg*. 2012;99(4):454-468. doi:10.1002/bjs.8697

124. Mckenna NP, Behm KT, Ubl DS, et al. Analysis of postoperative venous thromboembolism in patients with chronic ulcerative colitis: Is it the disease or the operation? In: *Diseases of the Colon and Rectum*. Vol 60. ; 2017:714-722. doi:10.1097/DCR.0000000000000846

125. Takahashi KI, Funayama Y, Fukushima K, et al. Stoma-related complications in inflammatory bowel disease. *Dig Surg*. 2008;25(1):16-20. doi:10.1159/000117818

126. Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta-analysis: recurrence of Crohn’s disease after total colectomy with permanent ileostomy. *Aliment Pharmacol Ther*. 2017;45(3):381-390. doi:10.1111/apt.13886

127. Colombo F, Pellino G, Selvaggi F, et al. Minimally invasive surgery and stoma-related complications after restorative proctocolectomy for ulcerative colitis. A two-centre comparison with open approach. *Am J Surg*. 2019;217(4):682-688. doi:10.1016/j.amjsurg.2018.07.028

128. Chow A, Tilney HS, Paraskeva P, Jeyarajah S, Zacharakis E, Purkayastha S. The morbidity surrounding reversal of defunctioning ileostomies: a systematic review of 48 studies including 6,107 cases. *Int J Colorectal Dis*. 2009;24(6):711-723. doi:10.1007/s00384-009-0660-z

129. Mantzouranis G, Fafliora E, Glanztounis G, Christodoulou DK, Katsanos KH. Inflammatory Bowel Disease and Sexual Function in Male and Female Patients: An Update on Evidence in the Past Ten Years. *J Crohn’s Colitis*. 2015;9(12):1160-1168. doi:10.1093/ecco-jcc/jjv140

130. Ahmed Ali U, Keus F, Heikens JT, et al. Open versus laparoscopic (assisted) ileo pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis. *Cochrane database Syst Rev*. 2009;(1):CD006267. doi:https://dx.doi.org/10.1002/14651858.CD006267.pub2

131. Lavryk OA, Stocchi L, Ashburn JH, et al. Case-Matched Comparison of Long-Term Functional and Quality of Life Outcomes Following Laparoscopic Versus Open Ileal Pouch-Anal Anastomosis. *World J Surg*. 2018;42(11):3746-3754. doi:10.1007/s00268-018-4602-1

132. Kjaer MD, Laursen SB, Qvist N, Kjeldsen J, Poornoroozy PH. Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis. *World J Surg*. 2014;38(9):2460-2465. doi:https://dx.doi.org/10.1007/s00268-014-2557-4

133. Farouk R, Pemberton JH, Wolff BG, Dozois RR, Browning S, Larson D. Functional Outcomes After Ileal Pouch-Anal Anastomosis for Chronic Ulcerative Colitis. *Ann Surg*. 2000;231(6):919. doi:10.1097/00000658-200006000-00017

134. Wang JY, Hart SL, Wilkowski KSY, et al. Gender-specific differences in pelvic organ function after proctectomy for inflammatory bowel disease. *Dis Colon Rectum*. 2011;54(1):66-76. doi:10.1007/DCR.0b013e3181fd48d2

135. Gklavas A, Kyprianou C, Exarchos G, Metaxa L, Dellis A, Papaconstantinou I. Sexual function after proctectomy in patients with inflammatory bowel disease: A prospective study. *Turkish J Gastroenterol*. 2019;30(11):943. doi:10.5152/TJG.2019.18676

136. Davies RJ, O’Connor BI, Victor C, MacRae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2008;51(7):1032-1035. doi:https://dx.doi.org/10.1007/s10350-008-9248-x

137. Gorgun E, Remzi FH, Montague DK, Connor JT, O’Brien K, Loparo B. Male sexual function improves after ileal pouch anal anastomosis. *Color Dis*. 2005;7(6):545-550. doi:http://dx.doi.org/10.1111/j.1463-1318.2005.00895.x

138. Lindsey I, George BD, Kettlewell MGW, Mortensen NJMC. Impotence after mesorectal and close rectal dissection for inflammatory bowel disease. In: *Diseases of the Colon and Rectum*. Vol 44. ; 2001:831-835. doi:10.1007/BF02234703

139. Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra®) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. *Dis Colon Rectum*. 2002;45(6):727-732. doi:10.1007/s10350-004-6287-9

140. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: A systematic review. *Dis Colon Rectum*. 2007;50(8):1128-1138. doi:10.1007/s10350-007-0240-7

141. Cornish J, Wooding K, Tan E, Nicholls RJ, Clark SK, Tekkis PP. Study of sexual, urinary, and fecal function in females following restorative proctocolectomy. *Inflamm Bowel Dis*. 2012;18(9):1601-1607. doi:10.1002/ibd.21910

142. Sunde ML, Øresland T, Engebreth Faerden A. Correlation between pouch function and sexual function in patients with IPAA. *Scand J Gastroenterol*. 2016;51(3):295-303. doi:https://dx.doi.org/10.3109/00365521.2015.1093165

143. Ogilvie JW, Goetz L, Baxter NN, Park J, Minami S, Madoff RD. Female sexual dysfunction after ileal pouch-anal anastomosis. In: *British Journal of Surgery*. Vol 95. John Wiley & Sons, Ltd; 2008:887-892. doi:10.1002/bjs.6072

144. Waljee A, Waljee J, Morris AM, Higgins PDR. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. *Gut*. 2006;55(11):1575-1580. doi:10.1136/gut.2005.090316

145. Rajaratnam SG, Eglinton TW, Hider P, Fearnhead NS. Impact of ileal pouch-anal anastomosis on female fertility: Meta-analysis and systematic review. *Int J Colorectal Dis*. 2011;26(11):1365-1374. doi:10.1007/s00384-011-1274-9

146. Lee S, Crowe M, Seow CH, et al. The impact of surgical therapies for inflammatory bowel disease on female fertility. *Cochrane database Syst Rev*. 2019;7(7):CD012711. doi:10.1002/14651858.CD012711.pub2

147. Sriranganathan D, Poo S, Segal JP. The impact of the ileoanal pouch on female fertility in ulcerative colitis: A systematic review and meta-analysis. *Color Dis*. April 2022. doi:10.1111/codi.16123

148. Olsen KØ, Juul S, Berndtsson I, Öresland T. Ulcerative colitis: Female fecundity before diagnosis, during disease, and after surgery compared with a population sample. *Gastroenterology*. 2002;122(1):15-19. doi:10.1053/gast.2002.30345

149. Bartels SAL, D’Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. *Ann Surg*. 2012;256(6):1045-1048. doi:https://dx.doi.org/10.1097/SLA.0b013e318250caa9

150. Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. *Ann Surg*. 2013;258(2):275-282. doi:https://dx.doi.org/10.1097/SLA.0b013e3182813741

151. Gorgun E, Cengiz TB, Aytac E, et al. Does laparoscopic ileal pouch-anal anastomosis reduce infertility compared with open approach? *Surgery*. 2019;166(4):670-677. doi:10.1016/j.surg.2019.04.045

152. Lightner AL, Mathis KL, Dozois EJ, et al. Results at Up to 30 Years after Ileal Pouch-Anal Anastomosis for Chronic Ulcerative Colitis. *Inflamm Bowel Dis*. 2017;23(5):781-790. doi:10.1097/MIB.0000000000001061

153. Lightner AL, Jia X, Zaghiyan K, Fleshner PR. IPAA in Known Preoperative Crohn’s Disease: A Systematic Review. *Dis Colon Rectum*. 2021;64(3):355-364. doi:10.1097/DCR.0000000000001918

154. Shen B, Kochhar GS, Kariv R, et al. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. *lancet Gastroenterol Hepatol*. 2021;6(10):826-849. doi:10.1016/S2468-1253(21)00101-1

155. Barnes EL, Holubar SD, Herfarth HH. Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis. *J Crohns Colitis*. 2021;15(8):1272-1278. doi:10.1093/ecco-jcc/jjab025

156. Kayal M, Plietz M, Rizvi A, et al. Inflammatory Pouch Conditions Are Common After Ileal Pouch Anal Anastomosis in Ulcerative Colitis Patients. *Inflamm Bowel Dis*. 2020;26(7):1079-1086. doi:10.1093/ibd/izz227

157. Shen B, Kochhar GS, Rubin DT, et al. Treatment of pouchitis, Crohn’s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. *lancet Gastroenterol Hepatol*. 2022;7(1):69-95. doi:10.1016/S2468-1253(21)00214-4

158. Lovegrove RE, Constantinides VA, Heriot AG, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: A meta-analysis of 4183 patients. *Ann Surg*. 2006;244(1):18-26. doi:10.1097/01.sla.0000225031.15405.a3

159. Abdalla M, Norblad R, Olsson M, et al. Anorectal Function After Ileo-Rectal Anastomosis Is Better than Pelvic Pouch in Selected Ulcerative Colitis Patients. *Dig Dis Sci*. 2020;65(1):250-259. doi:10.1007/s10620-019-05757-6

160. Lepisto A, Jarvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. *Scand J Surg*. 2005;94(1):40-42. doi:https://doi.org/10.1177/145749690509400110

161. Bælum JK, Qvist N, Ellebæk MB. Ileorectal anastomosis in patients with Crohn’s disease. Postoperative complications and functional outcome—a systematic review. *Color Dis*. 2021;23(10):2501-2514. doi:10.1111/codi.15839

162. Uzzan M, Cosnes J, Amiot A, et al. Long-term Follow-up after Ileorectal Anastomosis for Ulcerative Colitis. *Ann Surg*. 2017;266(6):1029-1034. doi:10.1097/SLA.0000000000002022

163. Landerholm K, Abdalla M, Myrelid P, Andersson RE. Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study. *Scand J Gastroenterol*. 2017;52(5):531-535. doi:10.1080/00365521.2016.1278457

164. Pellino G, Rottoli M, Mineccia M, et al. Segmental Versus Total Colectomy for Crohn’s Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study. *J Crohn’s Colitis*. July 2022. doi:10.1093/ecco-jcc/jjac096

165. Scaringi S, Di Bella A, Boni L, et al. New perspectives on the long-term outcome of segmental colectomy for Crohn’s colitis: an observational study on 200 patients. *Int J Colorectal Dis*. 2018;33(4):479-485. doi:10.1007/s00384-018-2998-6

166. Camilleri-Brennan J, Munro A, Steele RJC. Does an ileoanal pouch offer a better quality of life than a permanent ileostomy for patients with ulcerative colitis? *J Gastrointest Surg*. 2003;7(6):814-819. doi:10.1016/S1091-255X(03)00103-3

167. Murphy PB, Khot Z, Vogt KN, Ott M, Dubois L. Quality of Life After Total Proctocolectomy With Ileostomy or IPAA. *Dis Colon Rectum*. 2015;58(9):899-908. doi:10.1097/DCR.0000000000000418

168. Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs Ileostomy. *Dis Colon Rectum*. 2012;55(11):1131-1137. doi:10.1097/DCR.0b013e3182690870

169. O’Bichere A, Wilkinson K, Rumbles S, Norton C, Green C, Phillips RKS. Functional outcome after restorative panproctocolectomy for ulcerative colitis decreases an otherwise enhanced quality of life. *Br J Surg*. 2000;87(6):802-807. doi:10.1046/j.1365-2168.2000.01404.x

170. Nordin K, Påhlman L, Larsson K, Sundberg-Hjelm M, Lööf L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. *Scand J Gastroenterol*. 2002;37(4):450-457. doi:10.1080/003655202317316097

171. Pemberton JH, Phillips SF, Ready RR, Zinsmeister AR, Beahrs OH. Quality of life after Brooke Ileostomy and ileal pouch-anal anastomosis. Comparison of performance status. *Ann Surg*. 1989;209(5):620-628. doi:10.1097/00000658-198905000-00015

172. Weinryb RM, Liljeqvist L, Poppen B, Gustavsson JP. A longitudinal study of long-term quality of life after ileal pouch-anal anastomosis. *Am J Surg*. 2003;185(4):333-338. doi:10.1016/s0002-9610(02)01424-1

173. Derikx LAAP, Nissen LHC, Smits LJT, Shen B, Hoentjen F. Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2016;14(6):798-806.e20. doi:10.1016/j.cgh.2015.08.042

174. Abdalla M, Landerholm K, Andersson P, Andersson RE, Myrelid P. Risk of Rectal Cancer After Colectomy for Patients With Ulcerative Colitis: A National Cohort Study. *Clin Gastroenterol Hepatol*. 2017;15(7):1055-1060.e2. doi:10.1016/j.cgh.2016.11.036

175. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. *Inflamm Bowel Dis*. 2014;20(7):1296-1308. doi:https://dx.doi.org/10.1097/MIB.0000000000000026

176. Kariv R, Remzi FH, Lian L, et al. Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. *Gastroenterology*. 2010;139(3):806-812.e2. doi:10.1053/j.gastro.2010.05.085

177. Kuiper T, Vlug MS, van den Broek FJC, et al. The prevalence of dysplasia in the ileoanal pouch following restorative proctocolectomy for ulcerative colitis with associated dysplasia. *Color Dis*. 2012;14(4):469-473. doi:10.1111/j.1463-1318.2011.02669.x

178. Uzzan M, Kirchgesner J, Oubaya N, et al. Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. *J Crohns Colitis*. 2017;11(8):930-935. doi:10.1093/ecco-jcc/jjx027

179. Maser EA, Sachar DB, Kruse D, Harpaz N, Ullman T, Bauer JJ. High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn’s colitis. *Inflamm Bowel Dis*. 2013;19(9):1827-1832. doi:https://dx.doi.org/10.1097/MIB.0b013e318289c166

180. Radice E, Nelson H, Devine RM, et al. Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. *Dis Colon Rectum*. 1998;41(1):11-17. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9510305.

181. Gorfine SR, Harris MT, Bub DS, Bauer JJ. Restorative proctocolectomy for ulcerative colitis complicated by colorectal cancer. *Dis Colon Rectum*. 2004;47(8):1377-1385. doi:10.1007/s10350-004-0588-x

182. Wu X, Kiran RP, Remzi FH, Katz S, Mukewar S, Shen B. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. *J Crohn’s Colitis*. 2013;7(10):e419-e426. doi:10.1016/j.crohns.2013.01.017

183. Ten Hove JR, Bogaerts JMK, Bak MTJ, et al. Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2019;25(2):377-384. doi:https://dx.doi.org/10.1093/ibd/izy253

184. Sigel JE, Petras RE, Lashner BA, Fazio VW, Goldblum JR. Intestinal adenocarcinoma in Crohn’s disease: A report of 30 cases with a focus on coexisting dysplasia. *Am J Surg Pathol*. 1999;23(6):651-655. doi:10.1097/00000478-199906000-00003

185. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. *Histopathology*. 2007;50(5):574-583. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med5&NEWS=N&AN=17394493.

186. Krugliak Cleveland N, Colman RJ, Rodriquez D, et al. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. *Inflamm Bowel Dis*. 2016;22(3):631-637. doi:10.1097/MIB.0000000000000634

187. Khan N, Cole E, Shah Y, Paulson EC. Segmental resection is a safe oncological alternative to total proctocolectomy in elderly patients with ulcerative colitis and malignancy. *Color Dis*. 2017;19(12):1108-1116. doi:10.1111/codi.13721

188. Krugliak Cleveland N, Ollech JE, Colman RJ, et al. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. *Clin Gastroenterol Hepatol*. 2019;17(1):205-206. doi:10.1016/j.cgh.2018.04.061

189. Sensi B, Khan J, Warusavitarne J, et al. Long-term Oncological Outcome of Segmental Versus Extended Colectomy for Colorectal Cancer in Crohn’s Disease: Results from an International Multicentre Study. *J Crohn’s Colitis*. 2021;16(6):954-962. doi:10.1093/ecco-jcc/jjab215

190. Cohan JN, Ozanne EM, Sewell JL, et al. A Novel Decision Aid for Surgical Patients with Ulcerative Colitis. *Dis Colon Rectum*. 2016;59(6):520-528. doi:10.1097/DCR.0000000000000572

191. Kim AH, Girgis A, Karimi N, et al. A web-based decision aid (myAID) to enhance quality of life, empowerment, decision making, and disease control for patients with ulcerative colitis: Protocol for a cluster randomized controlled trial. *JMIR Res Protoc*. 2020;9(7):e15994. doi:10.2196/15994

192. Siegel C. *Evaluating a Shared Decision Making Program for Crohn’s Disease*.; 2014. https://clinicaltrials.gov/ct2/show/NCT02084290. Accessed November 4, 2020.

193. Perry-Woodford Z, Evans S. The Role of the Ileoanal Pouch Nurse Practitioner. In: *The Ileoanal Pouch*. Cham: Springer International Publishing; 2019:131-152. doi:10.1007/978-3-319-94385-5\_11

194. Thorpe G, McArthur M, Richardson B. Healthcare experiences of patients following faecal output stoma-forming surgery: A qualitative exploration. *Int J Nurs Stud*. 2014;51(3):379-389. doi:10.1016/J.IJNURSTU.2013.06.014